John C. Jr. Burnett
#87,980
Most Influential Person Now
John C. Jr. Burnett's AcademicInfluence.com Rankings
John C. Jr. Burnettmedical Degrees
Medical
#887
World Rank
#1148
Historical Rank
Cardiology
#44
World Rank
#44
Historical Rank
John C. Jr. Burnettphilosophy Degrees
Philosophy
#3172
World Rank
#5194
Historical Rank
Logic
#992
World Rank
#1603
Historical Rank
Download Badge
Medical Philosophy
John C. Jr. Burnett's Degrees
- PhD Cardiology Stanford University
- Doctorate Medicine Stanford University
Why Is John C. Jr. Burnett Influential?
(Suggest an Edit or Addition)John C. Jr. Burnett's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. (2003) (3005)
- Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. (2007) (1532)
- Plasma brain natriuretic peptide concentration: impact of age and gender. (2002) (1135)
- Circulating and tissue endothelin immunoreactivity in advanced atherosclerosis. (1991) (1019)
- Atrial natriuretic peptide elevation in congestive heart failure in the human. (1986) (897)
- Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: the EVEREST Clinical Status Trials. (2007) (818)
- Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. (1993) (787)
- The frequency of familial dilated cardiomyopathy in a series of patients with idiopathic dilated cardiomyopathy. (1992) (683)
- Endothelin in human congestive heart failure. (1994) (620)
- Progression of left ventricular diastolic dysfunction and risk of heart failure. (2011) (574)
- Effects of synthetic atrial natriuretic factor on renal function and renin release. (1984) (552)
- Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. (1996) (544)
- Integrated cardiac, renal, and endocrine actions of endothelin. (1989) (516)
- Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor. (1988) (491)
- Natriuretic peptide system in human heart failure. (1993) (482)
- Long-term L-arginine supplementation improves small-vessel coronary endothelial function in humans. (1998) (426)
- Prevalence and Prognostic Significance of Heart Failure Stages: Application of the American College of Cardiology/American Heart Association Heart Failure Staging Criteria in the Community (2007) (417)
- Consensus recommendations for the management of chronic heart failure: Introduction (1999) (391)
- Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: findings from the EVEREST trial. (2013) (388)
- BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases. (2004) (376)
- Congestion in acute heart failure syndromes: an essential target of evaluation and treatment. (2006) (376)
- Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. (1995) (376)
- Endothelin in coronary endothelial dysfunction and early atherosclerosis in humans. (1995) (364)
- Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide in the general community: determinants and detection of left ventricular dysfunction. (2006) (363)
- Remodeling and reparation of the cardiovascular system. (1992) (341)
- Circulating N-terminal atrial natriuretic peptide as a marker for symptomless left-ventricular dysfunction (1993) (337)
- Radiocontrast medium-induced declines in renal function: a role for oxygen free radicals. (1990) (329)
- Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix Metalloproteinases (2002) (312)
- Atrial natriuretic peptide frameshift mutation in familial atrial fibrillation. (2008) (310)
- Increased endothelin in experimental heart failure. (1990) (303)
- Vasopeptidase Inhibitors: A New Therapeutic Concept in Cardiovascular Disease? (2001) (303)
- Plasma Brain Natriuretic Peptide to Detect Preclinical Ventricular Systolic or Diastolic Dysfunction: A Community-Based Study (2004) (278)
- Intact and altered endothelium in regulation of vasomotion. (1992) (274)
- Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure. (2005) (268)
- Presence of C-type natriuretic peptide in cultured human endothelial cells and plasma. (1992) (263)
- Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure. (2006) (247)
- Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. (1998) (246)
- Risks for renal dysfunction with cardiac angiography. (1986) (245)
- Renal localization and actions of adrenomedullin: a natriuretic peptide. (1995) (245)
- Biology of the natriuretic peptides. (2008) (242)
- Natriuretic peptide levels in atrial fibrillation: a prospective hormonal and Doppler-echocardiographic study. (2000) (236)
- Neutral endopeptidase inhibition and the natriuretic peptide system: an evolving strategy in cardiovascular therapeutics. (2013) (233)
- Natriuretic peptides in cardiovascular diseases: current use and perspectives. (2014) (220)
- Novel Therapeutic Approaches Targeting the Renin-Angiotensin System and Associated Peptides in Hypertension and Heart Failure (2019) (209)
- Endothelin Has Biological Actions at Pathophysiological Concentrations (1991) (208)
- Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. (2001) (203)
- Increased plasma concentrations of endothelin in congestive heart failure in humans. (1992) (199)
- Adenylate kinase-catalyzed phosphotransfer in the myocardium : increased contribution in heart failure. (1999) (198)
- Vasopeptidase inhibition: a new concept in blood pressure management. (1999) (197)
- Thrombin enhances the release of endothelin from cultured porcine aortic endothelial cells. (1989) (196)
- B-Type Natriuretic Peptide in Organic Mitral Regurgitation: Determinants and Impact on Outcome (2005) (194)
- Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time (2007) (192)
- Evaluation of brain natriuretic peptide as marker of left ventricular dysfunction and hypertrophy in the population (2000) (192)
- Cardiac secretion of adrenomedullin in human heart failure. (1996) (191)
- Rationale and design of the multicenter, randomized, double-blind, placebo-controlled study to evaluate the Efficacy of Vasopressin antagonism in Heart Failure: Outcome Study with Tolvaptan (EVEREST). (2005) (187)
- Continental differences in clinical characteristics, management, and outcomes in patients hospitalized with worsening heart failure results from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) program. (2008) (178)
- Clinical implications of QRS duration in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction. (2008) (178)
- Adrenomedullin: potential in physiology and pathophysiology. (2000) (176)
- Sildenafil and B-Type Natriuretic Peptide Acutely Phosphorylate Titin and Improve Diastolic Distensibility In Vivo (2011) (171)
- Amino-Terminal Pro-B-Type Natriuretic Peptide and B-Type Natriuretic Peptide: Biomarkers for Mortality in a Large Community-Based Cohort Free of Heart Failure (2006) (171)
- Circulating and Tissue Endothelin Immunoreactivit in Hypercholesterolemic Pigs (1993) (167)
- Natriuretic peptides and therapeutic applications (2007) (165)
- Design, synthesis, and actions of a novel chimeric natriuretic peptide: CD-NP. (2008) (162)
- Role for intrarenal adenosine in the renal hemodynamic response to contrast media. (1987) (158)
- C-type natriuretic peptide: a selective cardiovascular peptide. (1993) (158)
- Adrenomedullin suppresses mitogenesis in rat mesangial cells via cAMP pathway. (1995) (155)
- Plasma endothelin concentrations in humans with end-stage heart failure and after heart transplantation. (1992) (155)
- Inhibition of Endothelium‐Derived Relaxing Factor Enhances Endothelin‐Mediated Vasoconstriction (1992) (153)
- A role for calcium in radiocontrast-induced reductions in renal hemodynamics. (1985) (152)
- The natriuretic peptides in cardiovascular medicine. (2004) (151)
- Cardiovascular and renal actions of C-type natriuretic peptide. (1992) (149)
- Cardiorenal Actions of TRV120027, a Novel ß-Arrestin–Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure (2011) (148)
- The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. (2002) (148)
- SYSTEMIC AND RENAL HEMODYNAMIC DIFFERENCES BETWEEN FK506 AND CYCLOSPORINE IN LIVER TRANSPLANT RECIPIENTS (1993) (147)
- Identification of atrial natriuretic factor within ventricular tissue in hamsters and humans with congestive heart failure. (1988) (145)
- Endothelin in experimental congestive heart failure in the anesthetized dog. (1990) (144)
- Augmentation of the cardiac natriuretic peptides by beta-receptor antagonism: evidence from a population-based study. (1998) (142)
- Alternate circulating pro-B-type natriuretic peptide and B-type natriuretic peptide forms in the general population. (2007) (141)
- Action of C-type natriuretic peptide in isolated canine arteries and veins. (1993) (141)
- Clinical course of patients with hyponatremia and decompensated systolic heart failure and the effect of vasopressin receptor antagonism with tolvaptan. (2013) (138)
- A randomized comparison of the nephrotoxicity of iopamidol and diatrizoate in high risk patients undergoing cardiac angiography. (1991) (136)
- Cytoprotective effects of adrenomedullin in glomerular cell injury: central role of cAMP signaling pathway. (1997) (136)
- Defining high-sensitivity cardiac troponin concentrations in the community. (2013) (131)
- Endothelin: a new cardiovascular regulatory peptide. (1990) (131)
- Matrix Metalloproteinases: Pathways of Induction by Bioactive Molecules (2004) (130)
- Changes in renal function during hospitalization and soon after discharge in patients admitted for worsening heart failure in the placebo group of the EVEREST trial. (2011) (127)
- Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. (2013) (125)
- A functional role for endogenous atrial natriuretic peptide in a canine model of early left ventricular dysfunction. (1995) (125)
- Natriuretic peptides in the pathophysiology of congestive heart failure (2000) (124)
- Renal interstitial pressure and sodium excretion during renal vein constriction. (1980) (120)
- Effects of avertin versus xylazine-ketamine anesthesia on cardiac function in normal mice. (2001) (119)
- The cGMP Signaling Pathway as a Therapeutic Target in Heart Failure With Preserved Ejection Fraction (2013) (118)
- Soluble guanylate cyclase: a potential therapeutic target for heart failure (2013) (118)
- Clinical criteria and biochemical markers for the detection of systolic dysfunction. (2000) (118)
- Cardiorenal actions of neutral endopeptidase inhibition in experimental congestive heart failure. (1990) (116)
- Vascular actions of C-type natriuretic peptide in isolated porcine coronary arteries and coronary vascular smooth muscle cells. (1994) (114)
- Differential sensitivity to endothelin in canine arteries and veins. (1989) (114)
- Pharmacodynamics Pharmacodynamics of a Novel Designer Natriuretic Peptide, CD‐NP, in a First‐in‐Human Clinical Trial in Healthy Subjects (2009) (110)
- Membrane guanylyl cyclase receptors: an update (2006) (110)
- Effects of synthetic atrial natriuretic peptide on renal function and renin release in acute experimental heart failure. (1985) (109)
- A comprehensive, longitudinal description of the in-hospital and post-discharge clinical, laboratory, and neurohormonal course of patients with heart failure who die or are re-hospitalized within 90 days: analysis from the EVEREST trial (2012) (109)
- The prognostic value of N-terminal pro-B-type natriuretic peptide for death and cardiovascular events in healthy normal and stage A/B heart failure subjects. (2010) (108)
- Immunoreactivity and Guanosine 3′,5′-Cyclic Monophosphate Activating Actions of Various Molecular Forms of Human B-Type Natriuretic Peptide (2007) (107)
- Atrial natriuretic peptide in heart failure. (1993) (106)
- Elevation of plasma endothelin associated with systemic hypertension in humans following orthotopic liver transplantation. (1991) (106)
- Targeting Heme-Oxidized Soluble Guanylate Cyclase in Experimental Heart Failure (2007) (102)
- Low Dose Nesiritide and the Preservation of Renal Function in Patients With Renal Dysfunction Undergoing Cardiopulmonary-Bypass Surgery: A Double-Blind Placebo-Controlled Pilot Study (2007) (101)
- Failing energetics in failing hearts (2000) (100)
- Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. (1997) (99)
- Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses Furosemide-Induced Aldosterone Activation in Experimental Heart Failure (2004) (99)
- Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation. (2007) (98)
- Enhanced Coronary Vasoconstriction to Endothelin-BReceptor Activation in Experimental Congestive Heart Failure (1996) (98)
- The Aging Heart, Myocardial Fibrosis, and its Relationship to Circulating C-Type Natriuretic Peptide (2011) (97)
- Cardiorenal and Humoral Properties of a Novel Direct Soluble Guanylate Cyclase Stimulator BAY 41-2272 in Experimental Congestive Heart Failure (2003) (97)
- Cardiotrophin-1 Stimulation of Cardiac Fibroblast Growth: Roles for Glycoprotein 130/Leukemia Inhibitory Factor Receptor and the Endothelin Type A Receptor (2002) (96)
- BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure. (1997) (96)
- Modulation of NO and endothelin by chronic increases in blood flow in canine femoral arteries. (1992) (95)
- Corin is present in the normal human heart, kidney, and blood, with pro-B-type natriuretic peptide processing in the circulation. (2011) (93)
- Role of endothelin receptor subtypes in the in vivo regulation of renal function. (1995) (93)
- B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities. (2005) (93)
- Escape from the sodium-retaining effects of mineralocorticoids. (1980) (93)
- Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate. (2008) (92)
- Angiotensin inhibition potentiates the renal responses to neutral endopeptidase inhibition in dogs with congestive heart failure. (1991) (92)
- Novel protein therapeutics for systolic heart failure: chronic subcutaneous B-type natriuretic peptide. (2012) (89)
- Novel Bifunctional Natriuretic Peptides as Potential Therapeutics* (2008) (88)
- TRV120027, a Novel &bgr;-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure (2012) (87)
- Assessment of left ventricular end-diastolic pressure by Doppler echocardiography: contribution of duration of pulmonary venous versus mitral flow velocity curves at atrial contraction. (1997) (87)
- Increased production of nitric oxide in coronary arteries during congestive heart failure. (1994) (87)
- Effect of Neprilysin Inhibition on Various Natriuretic Peptide Assays. (2019) (85)
- Cardiorenal and Neurohumoral Function in a Canine Model of Early Left Ventricular Dysfunction (1993) (84)
- Therapeutic actions of a new synthetic vasoactive and natriuretic peptide, dendroaspis natriuretic peptide, in experimental severe congestive heart failure. (2001) (84)
- Blunted cGMP response to agonists and enhanced glomerular cyclic 3',5'-nucleotide phosphodiesterase activities in experimental congestive heart failure. (1996) (84)
- Human hypertension is characterized by a lack of activation of the antihypertensive cardiac hormones ANP and BNP. (2012) (83)
- Radiocontrast increases plasma and urinary endothelin. (1991) (83)
- Weight changes after hospitalization for worsening heart failure and subsequent re-hospitalization and mortality in the EVEREST trial. (2009) (83)
- National Heart, Lung, and Blood Institute working group on emergency department management of acute heart failure: research challenges and opportunities. (2010) (82)
- Progression of preclinical diastolic dysfunction to the development of symptoms (2010) (82)
- A genetic variant of the atrial natriuretic peptide gene is associated with cardiometabolic protection in the general community. (2011) (81)
- Ventricular Structure and Function in Aged Dogs With Renal Hypertension: A Model of Experimental Diastolic Heart Failure (2005) (81)
- Natriuretic peptide system and endothelin in aneurysmal subarachnoid hemorrhage. (1997) (80)
- Limitations of estimating glomerular filtration rate from serum creatinine in the general population. (2006) (80)
- Mineralocorticoid Accelerates Transition to Heart Failure With Preserved Ejection Fraction Via “Nongenomic Effects” (2010) (79)
- THE CONCISE GUIDE TO PHARMACOLOGY 2021/22: Catalytic receptors (2021) (79)
- Short-term Clinical Effects of Tolvaptan, an Oral Vasopressin Antagonist, in Patients Hospitalized for Heart Failure (2007) (79)
- Experimental mild renal insufficiency mediates early cardiac apoptosis, fibrosis, and diastolic dysfunction: a kidney-heart connection. (2012) (78)
- Hormonal determinants of sodium excretion in rats with experimental high-output heart failure. (1988) (77)
- Neutral endopeptidase inhibition potentiates the natriuretic actions of adrenomedullin. (1998) (77)
- Presence of C-type natriuretic peptide in human kidney and urine. (1994) (76)
- Prevalence of coronary blood flow reserve abnormalities among patients with nonobstructive coronary artery disease and chest pain. (1998) (74)
- Enhanced coronary vasoconstriction to endothelin-B-receptor activation in experimental congestive heart failure. (1996) (73)
- The renal action of atrial natriuretic peptide during control of glomerular filtration. (1986) (73)
- Role of hydrostatic and oncotic pressures in renal sodium reabsorption. (1983) (73)
- Long-Term Cardiac pro-B-Type Natriuretic Peptide Gene Delivery Prevents the Development of Hypertensive Heart Disease in Spontaneously Hypertensive Rats (2011) (71)
- Variable phenotype in murine transverse aortic constriction. (2012) (71)
- Augmented cardiac cardiotrophin-1 in experimental congestive heart failure. (2000) (70)
- NT-proBNP: The Gold Standard Biomarker in Heart Failure. (2016) (69)
- Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction. (2006) (69)
- Angiotensin converting enzyme inhibition modulates endogenous endothelin in chronic canine thoracic inferior vena caval constriction. (1996) (69)
- ANP inhibits Na(+)-H+ antiport in proximal tubular brush border membrane: role of dopamine. (1990) (69)
- Immunohistochemical localization of adrenomedullin in canine heart and aorta (1995) (69)
- Effects of natriuretic peptides on load and myocardial function in normal and heart failure dogs. (2000) (68)
- ANF-mediated renal cGMP generation in congestive heart failure. (1991) (68)
- Angiotensin II in the evolution of experimental heart failure. (1996) (68)
- Effects of tolvaptan on dyspnoea relief from the EVEREST trials. (2009) (68)
- Pro-B-type natriuretic peptide(1-108) circulates in the general community: plasma determinants and detection of left ventricular dysfunction. (2011) (67)
- Impaired natriuretic and renal endocrine response to acute volume expansion in pre-clinical systolic and diastolic dysfunction. (2011) (67)
- Role of endogenous atrial natriuretic factor in acute congestive heart failure. (1989) (67)
- Effect of inhibition of converting enzyme on renal hemodynamics and sodium management in polycystic kidney disease. (1991) (67)
- Natriuretic peptide receptors and neutral endopeptidase in mediating the renal actions of a new therapeutic synthetic natriuretic peptide dendroaspis natriuretic peptide. (2002) (66)
- Modulation of cGMP in heart failure: a new therapeutic paradigm. (2009) (66)
- Atrial natriuretic peptide in hypothyroidism. (1987) (65)
- Endothelium-derived relaxing factor in regulation of basal cardiopulmonary and renal function. (1991) (65)
- Subcutaneous administration of the cardiac hormone BNP in symptomatic human heart failure. (2004) (64)
- Circulating aldosterone and natriuretic peptides in the general community: relationship to cardiorenal and metabolic disease. (2015) (64)
- Chronic oral endothelin type A receptor antagonism in experimental heart failure. (1998) (64)
- BNP‐induced activation of cGMP in human cardiac fibroblasts: Interactions with fibronectin and natriuretic peptide receptors (2006) (63)
- Nitric oxide-independent stimulation of soluble guanylate cyclase with BAY 41-2272 in cardiovascular disease. (2007) (63)
- Renal effects of ANP without changes in glomerular filtration rate and blood pressure. (1986) (63)
- Failure of atrial natriuretic factor to increase with volume expansion in acute and chronic congestive heart failure in the dog. (1989) (62)
- Oral Human Brain Natriuretic Peptide Activates Cyclic Guanosine 3,5-Monophosphate and Decreases Mean Arterial Pressure (2005) (62)
- Participation bias in a population-based echocardiography study. (2004) (62)
- Carvedilol therapy is associated with a sustained decline in brain natriuretic peptide levels in patients with congestive heart failure. (2005) (62)
- Effect of converting-enzyme inhibition on renal response to ANF in rats with experimental heart failure. (1990) (61)
- Use of plasma brain natriuretic peptide concentration to aid in the diagnosis of heart failure. (2003) (61)
- Cardio-renal-endocrine dynamics during stepwise infusion of physiologic and pharmacologic concentrations of atrial natriuretic factor in the dog. (1987) (61)
- Autocrine role for the endothelin-B receptor in the secretion of adrenomedullin. (1998) (61)
- Endothelium-derived relaxing factor in pulmonary and renal circulations during hypoxia. (1992) (60)
- C-Type Natriuretic Peptide-Induced Vasodilation Is Dependent On Hyperpolarization in Human Forearm Resistance Vessels (2001) (60)
- Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload. (2005) (59)
- Long‐Term Hypotensive and Renal Effects of Atrial Natriuretic Peptide (1986) (58)
- Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. (2006) (58)
- CD-NP: A Novel Engineered Dual Guanylyl Cyclase Activator with Anti-Fibrotic Actions in the Heart (2012) (58)
- Endogenous Natriuretic Peptides Participate in Renal and Humoral Actions of Acute Vasopeptidase Inhibition in Experimental Mild Heart Failure (2001) (58)
- Vasonatrin peptide: a unique synthetic natriuretic and vasorelaxing peptide. (1993) (58)
- Natriuretic peptides in the diagnosis and management of chronic heart failure. (2009) (57)
- The role of neutral endopeptidase in dogs with evolving congestive heart failure. (1995) (57)
- Maximizing the renal cyclic 3'-5'-guanosine monophosphate system with type V phosphodiesterase inhibition and exogenous natriuretic peptide: a novel strategy to improve renal function in experimental overt heart failure. (2006) (56)
- Predictive utility of atrial, N-terminal pro-atrial, and N-terminal pro-B-type natriuretic peptides for mortality and cardiovascular events in the general community: a 9-year follow-up study. (2011) (56)
- Effects of atrial natriuretic peptide on renin secretion in nonfiltering kidney. (1986) (56)
- Frequency of familial dilated cardiomyopathy. (1995) (56)
- Dendroaspis natriuretic peptide relaxes isolated human arteries and veins. (2002) (55)
- Ventricular remodeling during development and recovery from modified tachycardia-induced cardiomyopathy model. (1996) (55)
- Low-dose nesiritide in human anterior myocardial infarction suppresses aldosterone and preserves ventricular function and structure: a proof of concept study (2009) (55)
- C-type natriuretic peptide immunoreactivity in human breast vascular endothelial cells (1992) (55)
- A human atrial natriuretic peptide gene mutation reveals a novel peptide with enhanced blood pressure-lowering, renal-enhancing, and aldosterone-suppressing actions. (2009) (54)
- Induction and prevention of radiocontrast-induced nephropathy in dogs with heart failure. (1990) (54)
- Load Versus Humoral Activation in the Genesis of Early Hypertensive Heart Disease (2001) (54)
- Endothelin at pathophysiological concentrations mediates coronary vasoconstriction via the endothelin-A receptor. (1995) (53)
- Secretion of glycosylated pro-B-type natriuretic peptide from normal cardiomyocytes. (2011) (52)
- Differential expression of the pro-natriuretic peptide convertases corin and furin in experimental heart failure and atrial fibrosis. (2013) (52)
- BNP molecular forms and processing by the cardiac serine protease corin. (2013) (52)
- Role of atrial natriuretic peptide in volume-expansion natriuresis. (1986) (52)
- Troponin, B‐type natriuretic peptides and outcomes in severe heart failure: Differences between ischemic and dilated cardiomyopathies (2007) (51)
- Molecular Forms of Atrial Natriuretic Factor in Normal and Failing Human Myocardium (1993) (51)
- Natriuretic and antialdosterone actions of chronic oral NEP inhibition during progressive congestive heart failure. (2005) (51)
- Differential Mechanisms of Ca2+ Release from Vascular Smooth Muscle Cell Microsomes (2002) (51)
- Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure. (2005) (50)
- Association of B-type natriuretic peptide activation to left ventricular end-systolic remodeling in organic and functional mitral regurgitation. (2006) (49)
- The relationship between atrial granularity and circulating atrial natriuretic peptide in hamsters with congestive heart failure. (1986) (49)
- Cardiac atrial natriuretic factor during evolution of congestive heart failure. (1992) (48)
- Natriuretic Peptides as Inclusion Criteria in Clinical Trials: A JACC Heart Failure Position Paper. (2020) (48)
- Cardiac fibrosis in end-stage human heart failure and the cardiac natriuretic peptide guanylyl cyclase system: regulation and therapeutic implications. (2014) (48)
- Coupling of a vented column with splitless nanoRPLC-ESI-MS for the improved separation and detection of brain natriuretic peptide-32 and its proteolytic peptides. (2009) (47)
- Pro–B-Type Natriuretic Peptide-1-108 Processing and Degradation in Human Heart Failure (2014) (47)
- C-type natriuretic peptide-mediated coronary vasodilation: role of the coronary nitric oxide and particulate guanylate cyclase systems. (1996) (47)
- Neutral endopeptidase inhibition potentiates the renal actions of atrial natriuretic factor. (1990) (47)
- Renal-specific actions of angiotensin II receptor antagonism in the anesthetized dog. (1992) (46)
- Differential Actions of Vasopeptidase Inhibition Versus Angiotensin-Converting Enzyme Inhibition on Diuretic Therapy in Experimental Congestive Heart Failure (2002) (46)
- Maximizing the Natriuretic Peptide System in Experimental Heart Failure: Subcutaneous Brain Natriuretic Peptide and Acute Vasopeptidase Inhibition (2002) (46)
- High-sensitivity troponin I and amino-terminal pro--B-type natriuretic peptide predict heart failure and mortality in the general population. (2014) (45)
- Angiotensin II AT1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure. (2003) (45)
- Biochemistry, Therapeutics, and Biomarker Implications of Neprilysin in Cardiorenal Disease. (2017) (45)
- Mineralocorticoid Signaling in Transition to Heart Failure With Normal Ejection Fraction (2008) (45)
- Revisiting salt and water retention: new diuretics, aquaretics, and natriuretics. (2003) (45)
- The Atrial Natriuretic Peptide Genetic Variant rs5068 Is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population (2013) (45)
- Reduced activity of enzymes coupling ATP-generating with ATP-consuming processes in the failing myocardium (2004) (44)
- Role of prostaglandins and renal nerves in the renal actions of adrenomedullin. (1997) (44)
- Biodesign of a renal-protective peptide based on alternative splicing of B-type natriuretic peptide (2009) (44)
- HFSA 2010 Guideline Executive Summary Executive Summary: HFSA 2010 Comprehensive Heart Failure Practice Guideline (2006) (44)
- Circulating beta-atrial natriuretic factor in congestive heart failure in humans. (1993) (44)
- B-Type Natriuretic Peptide Deletion Leads to Progressive Hypertension, Associated Organ Damage, and Reduced Survival: Novel Model for Human Hypertension (2015) (43)
- Mechanism of relaxations to C-type natriuretic peptide in veins. (1996) (43)
- GPCR biased ligands as novel heart failure therapeutics. (2013) (43)
- Vasopeptidase Inhibition Prevents Endothelial Dysfunction of Resistance Arteries in Salt-Sensitive Hypertension in Comparison With Single ACE Inhibition (2001) (42)
- Cardiovascular, Renal, and Endocrine Response to Atrial Natriuretic Peptide in Angiotensin II Mediated Hypertension (1986) (42)
- Acute hypoxia and endogenous renal endothelin. (1994) (42)
- Atrial natriuretic factor: implications in congestive heart failure and hypertension. (1989) (42)
- Decongestive therapy and renal function in acute heart failure: time for a new approach? (2014) (41)
- Differences in Natriuretic Peptide Levels by Race/Ethnicity (From the Multi-Ethnic Study of Atherosclerosis). (2017) (41)
- Only large reductions in concentrations of natriuretic peptides (BNP and NT-proBNP) are associated with improved outcome in ambulatory patients with chronic heart failure. (2009) (41)
- Restoration of renal response to atrial natriuretic factor in experimental low-output heart failure. (1989) (40)
- Renal response to atrial natriuretic factor is modulated by intrarenal angiotensin II. (1988) (40)
- Lower rather than higher levels of B-type natriuretic peptides (NT-pro-BNP and BNP) predict short-term mortality in end-stage heart failure patients treated with nesiritide. (2005) (40)
- Elevation of circulating but not myocardial FGF23 in human acute decompensated heart failure. (2016) (40)
- Atrial natriuretic peptide and C-type natriuretic peptide in spontaneously hypertensive rats and their vasorelaxing actions in vitro. (1994) (39)
- Cardiorenal endocrine dynamics during volume expansion in hypothyroid dogs. (1988) (39)
- The effects of nesiritide on renal function and diuretic responsiveness in acutely decompensated heart failure patients with renal dysfunction. (2008) (39)
- Cardiorenal syndrome in decompensated heart failure: Prognostic and therapeutic implications (2004) (39)
- Atrial Natriuretic Peptide Genetic Variant rs5065 and Risk for Cardiovascular Disease in the General Community: A 9-Year Follow-Up Study (2013) (39)
- CD-NP: An Innovative Designer Natriuretic Peptide Activator of Particulate Guanylyl Cyclase Receptors for Cardiorenal Disease (2010) (39)
- Experimental cardiac radiation exposure induces ventricular diastolic dysfunction with preserved ejection fraction. (2017) (38)
- Regulation of cardiac adrenomedullin in heart failure (2001) (38)
- Adrenomedullin in experimental congestive heart failure: cardiorenal activation. (1997) (38)
- Insulin/glucose induces natriuretic peptide clearance receptor in human adipocytes: a metabolic link with the cardiac natriuretic pathway. (2016) (38)
- Pharmacology of vasopressin antagonists (2008) (37)
- Effects of tolvaptan on physician-assessed symptoms and signs in patients hospitalized with acute heart failure syndromes: analysis from the efficacy of vasopressin antagonism in heart failure outcome study with tolvaptan (EVEREST) trials. (2011) (37)
- Atrial Natriuretic Peptide: A Molecular Target of Novel Therapeutic Approaches to Cardio-Metabolic Disease (2019) (37)
- Segmental analysis of sodium reabsorption during renal vein constriction. (1982) (36)
- Equimolar doses of atrial and brain natriuretic peptides and urodilatin have differential renal actions in overt experimental heart failure. (2005) (36)
- Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor (2019) (36)
- Modulation of functionally active endothelin-converting enzyme by chronic neutral endopeptidase inhibition in experimental atherosclerosis. (2000) (36)
- Cardiorenal syndrome: Multi‐organ dysfunction involving the heart, kidney and vasculature (2020) (36)
- New Pharmacological Strategies to Increase cGMP. (2016) (35)
- Physiologic and pathophysiologic roles of endothelin in the kidney. (1994) (35)
- Gender and relaxation to C-type natriuretic peptide in porcine coronary arteries. (1998) (35)
- PTH: Potential role in management of heart failure. (2014) (35)
- A Novel Atrial Natriuretic Peptide Based Therapeutic in Experimental Angiotensin II Mediated Acute Hypertension (2010) (35)
- Atrial natriuretic peptide during mineralocorticoid escape in the human. (1987) (35)
- The prognostic value of N-terminal proB-type natriuretic peptide (2005) (35)
- BNP: increasing importance in the pathophysiology and diagnosis of congestive heart failure. (1997) (35)
- Atrial natriuretic peptide in human essential hypertension. (1987) (35)
- Weight Loss, Saline Loading, and the Natriuretic Peptide System (2014) (35)
- Physiological significance of endothelin : its role in congestive heart failure (1993) (35)
- Endothelin in a model of acute ischemic renal dysfunction: modulating action of atrial natriuretic factor. (1992) (35)
- Activation of myocardial and renal natriuretic peptides during acute intravascular volume overload in dogs: functional cardiorenal responses to receptor antagonism. (1998) (34)
- A novel chimeric natriuretic peptide reduces cardiomyocyte hypertrophy through the NHE-1-calcineurin pathway. (2010) (34)
- Efficacy of oral tolvaptan in acute heart failure patients with hypotension and renal impairment (2012) (34)
- C-type natriuretic peptide has a negative inotropic effect on cardiac myocytes. (2001) (34)
- Mechanism of relaxations to dendroaspis natriuretic peptide in canine coronary arteries. (2000) (34)
- Role of natriuretic peptide clearance receptor in in vivo control of C-type natriuretic peptide. (1995) (34)
- Differential effects of natriuretic peptides and NO on LV function in heart failure and normal dogs. (2001) (34)
- Urinary C-type natriuretic peptide excretion: a potential novel biomarker for renal fibrosis during aging. (2011) (34)
- Circulating heart autoantibodies in familial as compared with nonfamilial idiopathic dilated cardiomyopathy. (1994) (34)
- Cardiac Micro–Computed Tomography Imaging of the Aging Coronary Vasculature (2012) (34)
- Renal role of the endogenous natriuretic peptide system in acute congestive heart failure. (1996) (33)
- Cardiorenal Actions of TRV 120027 , a Novel ß-Arrestin – Biased Ligand at the Angiotensin II Type I Receptor , in Healthy and Heart Failure Canines A Novel Therapeutic Strategy for Acute Heart Failure (2011) (33)
- Effects of atrial natriuretic factor in rats with experimental high-output heart failure. (1988) (33)
- Pathophysiology and the cardiorenal connection in heart failure. Circulating hormones: biomarkers or mediators. (2015) (33)
- Effect of low dose aspirin on cardiorenal function and acute hemodynamic response to enalaprilat in a canine model of severe heart failure. (1995) (33)
- Atrial Natriuretic Peptide and Treatment With Sacubitril/Valsartan in Heart Failure With Reduced Ejection Fraction. (2020) (33)
- Cardiorenal fibrosis and dysfunction in aging: Imbalance in mediators and regulators of collagen (2016) (33)
- Natriuretic response to volume expansion in polycystic kidney disease. (1989) (33)
- Biological role for the endothelin-A receptor in aortic cross-clamping. (1993) (32)
- Differential Regulation of ANP and BNP in Acute Decompensated Heart Failure: Deficiency of ANP. (2019) (32)
- TRV120027, a Novel Beta-Arrestin Biased Ligand at the Angiotensin II Type I Receptor, Unloads the Heart and Maintains Renal Function When Added to Furosemide in Experimental Heart Failure (2011) (32)
- Circulating C-Type Natriuretic Peptide and Its Relationship to Cardiovascular Disease in the General Population (2015) (32)
- Urinary C-type natriuretic peptide: a new heart failure biomarker. (2013) (32)
- The role of frequency of atrial contraction versus atrial pressure in atrial natriuretic peptide release. (1989) (32)
- Elevated levels of atrial natriuretic peptide during aldosterone escape. (1987) (31)
- Modulation of exogenous and endogenous atrial natriuretic peptide by a receptor inhibitor. (1994) (31)
- Possible modulation of release of atrial natriuretic factor by endothelium-derived relaxing factor. (1990) (31)
- Atrial natriuretic peptide and renal cGMP in rats with experimental heart failure. (1991) (31)
- Atrial natriuretic peptide levels during acute and chronic saline loading in conscious dogs. (1986) (30)
- Biological actions of brain natriuretic peptide in thoracic inferior vena caval constriction. (1993) (30)
- Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. (1999) (30)
- Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator That Goes Beyond Atrial and B-Type Natriuretic Peptides. (2015) (30)
- Sustained blood pressure-lowering actions of subcutaneous B-type natriuretic peptide (nesiritide) in a patient with uncontrolled hypertension. (2012) (30)
- Innovative Therapeutics (2016) (30)
- Endothelin A Receptor Antagonism in Experimental Congestive Heart Failure Results in Augmentation of the Renin-Angiotensin System and Sustained Sodium Retention (2004) (30)
- Adrenomedullin: an autocrine/paracrine factor for cardiorenal protection. (2002) (29)
- Pulmonary and urinary clearance of atrial natriuretic factor in acute congestive heart failure in dogs. (1991) (29)
- Enhanced endothelin-converting enzyme immunoreactivity in early atherosclerosis. (1998) (28)
- Clinical application of the natriuretic peptides in heart failure (2006) (28)
- Chronic Actions of a Novel Oral B-Type Natriuretic Peptide Conjugate in Normal Dogs and Acute Actions in Angiotensin II–Mediated Hypertension (2008) (28)
- Role of atrial natriuretic factor in the natriuresis of acute volume expansion. (1987) (28)
- Activation of cardiorenal and pulmonary tissue endothelin-1 in experimental heart failure. (2000) (28)
- Neutral endopeptidase regulates C-type natriuretic peptide metabolism but does not potentiate its bioactivity in vivo. (1997) (28)
- Endothelin in thoracic inferior vena caval constriction model of heart failure. (1992) (28)
- M‐Atrial Natriuretic Peptide and Nitroglycerin in a Canine Model of Experimental Acute Hypertensive Heart Failure: Differential Actions of 2 cGMP Activating Therapeutics (2014) (28)
- Particulate Guanylyl Cyclase A/cGMP Signaling Pathway in the Kidney: Physiologic and Therapeutic Indications (2018) (27)
- Increased plasma level of endothelin-1 in the Okamoto spontaneously hypertensive rat. (1993) (27)
- Natriuresis during and early after cardiopulmonary bypass: relationship to atrial natriuretic factor, aldosterone, and antidiuretic hormone. (1989) (27)
- Designer Natriuretic Peptides (2009) (27)
- Biomarker‐based risk prediction in the community (2016) (26)
- Aldosterone Predicts Cardiovascular, Renal, and Metabolic Disease in the General Community: A 4‐Year Follow‐Up (2015) (26)
- Role for the endogenous natriuretic peptide system in the control of basal coronary vascular tone in dogs. (1996) (26)
- Secretion of prohormone of B-type natriuretic peptide, proBNP1-108, is increased in heart failure. (2013) (25)
- A randomized trial of ecadotril versus placebo in patients with mild to moderate heart failure: the U.S. ecadotril pilot safety study. (1999) (25)
- CNP production in the kidney and effects of protein intake restriction in nephrotic syndrome. (2002) (25)
- A new role for the natriuretic peptides: metabolic regulators of the adipocyte. (2009) (25)
- Saxagliptin and Tadalafil Differentially Alter Cyclic Guanosine Monophosphate (cGMP) Signaling and Left Ventricular Function in Aortic‐Banded Mini‐Swine (2016) (25)
- Increase and uncoupling of adrenomedullin from the natriuretic peptide system in aneurysmal subarachnoid hemorrhage. (2001) (25)
- Atrial Natriuretic Peptide - Old But New Therapeutic in Cardiovascular Diseases. (2017) (24)
- Dystrophin analysis in idiopathic dilated cardiomyopathy. (1993) (24)
- Designer natriuretic peptides: a vision for the future of heart failure therapeutics. (2011) (24)
- A Pilot Study of Dendroaspis Natriuretic Peptide in Aneurysmal Subarachnoid Hemorrhage (2004) (24)
- A gut-heart connection in cardiometabolic regulation (2013) (24)
- Renal and Anti-Aldosterone Actions of Vasopressin-2 Receptor Antagonism and B-Type Natriuretic Peptide in Experimental Heart Failure (2010) (24)
- Adrenomedullin in experimental congestive heart failure: cardiorenal activation. (1997) (24)
- Differential atrial and ventricular expression of myocardial BNP during evolution of heart failure. (1998) (24)
- Prognostic markers in heart failure—congestion, neurohormones, and the cardiorenal syndrome (2007) (24)
- The Origin of Endothelin‐1 in Patients With Severe Preeclampsia (1997) (23)
- Effects of hypertonic saline infusion and water drinking on atrial peptide. (1986) (23)
- Urinary C-type natriuretic peptide: an emerging biomarker for heart failure and renal remodeling. (2015) (23)
- Chronic subcutaneous brain natriuretic peptide therapy in asymptomatic systolic heart failure (2016) (23)
- Utilizing spectral counting to quantitatively characterize tandem removal of abundant proteins (TRAP) in human plasma. (2010) (23)
- Effects of adrenomedullin on load and myocardial performance in normal and heart-failure dogs. (2000) (23)
- CRRL269: a novel designer and renal-enhancing pGC-A peptide activator. (2018) (22)
- Post-transcriptional modification of pro-BNP in heart failure: is glycosylation and circulating furin key for cardiovascular homeostasis? (2014) (22)
- The effect of the brain-type natriuretic peptide single-nucleotide polymorphism rs198389 on test characteristics of common assays. (2011) (22)
- Ventricular cardiotrophin-1 activation precedes BNP in experimental heart failure (2003) (22)
- Cenderitide: structural requirements for the creation of a novel dual particulate guanylyl cyclase receptor agonist with renal-enhancing in vivo and ex vivo actions. (2016) (22)
- Local renal delivery of a natriuretic peptide a renal-enhancing strategy for B-type natriuretic peptide in overt experimental heart failure. (2009) (22)
- Circulating Neprilysin in Patients with Heart Failure with Preserved Ejection Fraction. (2020) (22)
- Endothelial permeability in vitro and in vivo: Protective actions of ANP and omapatrilat in experimental atherosclerosis (2013) (22)
- B‐type natriuretic peptide and extracellular matrix protein interactions in human cardiac fibroblasts (2010) (21)
- A Human Study to Evaluate Safety, Tolerability, and Cyclic GMP Activating Properties of Cenderitide in Subjects With Stable Chronic Heart Failure (2018) (21)
- M-Atrial Natriuretic Peptide: A Novel Antihypertensive Protein Therapy (2012) (21)
- Expression of atrial natriuretic factor in the human ventricle is independent of chamber dilation. (1990) (21)
- The atrial peptide system in cardiac disease. (1988) (21)
- Utility of Doppler myocardial imaging, cardiac biomarkers, and clonal immunoglobulin genes to assess left ventricular performance and stratify risk following peripheral blood stem cell transplantation in patients with systemic light chain amyloidosis (Al). (2011) (21)
- Inhibition of cyclic GMP phosphodiesterases augments renal responses to atrial natriuretic factor in congestive heart failure. (1994) (20)
- Cardiorenal-endocrine dynamics during and following volume expansion. (1987) (20)
- A favorable cardiometabolic profile is associated with the G allele of the genetic variant rs5068 in African Americans: The Multi-Ethnic Study of Atherosclerosis (MESA) (2017) (20)
- Natriuretic peptide pharmacogenetics: membrane metallo-endopeptidase (MME): common gene sequence variation, functional characterization and degradation. (2010) (20)
- Soluble guanylate cyclase: not a dull enzyme. (2009) (20)
- Chronic Peptide Therapy With B-Type Natriuretic Peptide in Patients With Pre-Clinical Diastolic Dysfunction (Stage B Heart Failure). (2016) (20)
- Atrial endocrine function in humans with artificial hearts. (1986) (20)
- CNP is present in canine renal tubular cells and secreted by cultured opossum kidney cells. (1994) (20)
- Endothelin-mediated cardiorenal hemodynamic and neuroendocrine effects are attenuated by nitroglycerin in vivo. (1993) (19)
- Leukemia inhibitory factor is augmented in the heart in experimental heart failure (2003) (19)
- The renal, forearm, and hormonal responses to standing in the presence and absence of propranolol. (1986) (19)
- Novel therapeutic directions for the natriuretic peptides in cardiovascular diseases: what's on the horizon. (2006) (19)
- The tumultuous journey of nesiritide: past, present, and future. (2008) (19)
- Effect of cardiac resynchronization therapy on broad neurohormone biomarkers in heart failure (2011) (19)
- The role of coenzyme Q10 in the pathophysiology and therapy of experimental congestive heart failure in the dog. (2000) (18)
- Urocortin: advancing the neurohumoral hypothesis of heart failure. (2005) (18)
- Atrial natriuretic factor modulates whole kidney tubuloglomerular feedback. (1990) (18)
- Cardiotrophin-1 stimulates endothelin-1 via gp130 in vascular endothelial cells (2002) (18)
- Adrenomedullin as a renal regulator peptide. (2000) (18)
- Atrial and pulmonary endothelin mRNA is increased in a canine model of chronic low cardiac output. (1997) (18)
- Acetylcholine-induced vasodilation without natriuresis during control of interstitial pressure. (1982) (18)
- Nesiritide in acute decompensated heart failure: current status and future perspectives. (2008) (18)
- Improving limits of detection for B-type natriuretic peptide using PC-IDMS: an application of the ALiPHAT strategy. (2010) (17)
- Neutral endopeptidase 24.11: a modulator of natriuretic peptides. (1993) (17)
- Role for precursor Pro-B type natriuretic peptide in assessing response to therapy and prognosis in patients with decompensated heart failure treated with nesiritide. (2009) (17)
- B-type natriuretic peptide 8-32, which is produced from mature BNP 1-32 by the metalloprotease meprin A, has reduced bioactivity. (2009) (17)
- Endothelin-1 in bronchoalveolar lavage during rejection of allotransplanted lungs. (1994) (17)
- Low-dose atrial natriuretic factor and furosemide in experimental acute congestive heart failure. (1993) (17)
- Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated With Stroke in Whites (2014) (17)
- Effect of Testosterone on Natriuretic Peptide Levels. (2019) (17)
- Soluble Neprilysin in the General Population: Clinical Determinants and Its Relationship to Cardiovascular Disease (2019) (16)
- Natriuretic peptide based therapeutics for heart failure: Cenderitide: A novel first-in-class designer natriuretic peptide. (2019) (16)
- Atrial Natriuretic Peptide Decreases Cardiac Output Independent of Coronary Vasoconstriction (1987) (16)
- Erratum: Presence of C-type natriuretic peptide in human kidney and urine (Kidney International 46 (1994) (744-747)) (1996) (16)
- Dietary sodium modulation of aldosterone activation and renal function during the progression of experimental heart failure (2015) (16)
- C53: A novel particulate guanylyl cyclase B receptor activator that has sustained activity in vivo with anti-fibrotic actions in human cardiac and renal fibroblasts. (2019) (16)
- Ventricular adrenomedullin is associated with myocyte hypertrophy in human transplanted heart (2003) (16)
- Presence and secretion of atrial natriuretic peptide from cultured human aortic endothelial cells. (1995) (16)
- Actions of a novel synthetic natriuretic peptide on hemodynamics and ventricular function in the dog. (2002) (16)
- Clearance receptor-mediated control of atrial natriuretic factor in experimental congestive heart failure. (1994) (16)
- Effect of Neurohormonal Blockade Drug Therapy on Outcomes and Left Ventricular Function and Structure After Left Ventricular Assist Device Implantation. (2016) (16)
- Baseline and serial neurohormones in patients with congestive heart failure treated with and without bucindolol: results of the neurohumoral substudy of the Beta-Blocker Evaluation of Survival Study (BEST). (2007) (16)
- Rationale and Therapeutic Opportunities for Natriuretic Peptide System Augmentation in Heart Failure (2015) (15)
- Renal interstitial pressure in mineralocorticoid escape. (1985) (15)
- Adrenomedullin-mediated relaxations in veins are endothelium-dependent and distinct from arteries. (1997) (15)
- Atrial BNP endocrine function during chronic unloading of the normal canine heart. (2005) (15)
- New Cardioprotective Agent K201 Is Natriuretic and Glomerular Filtration Rate Enhancing (2006) (15)
- What stimulates atrial natriuretic factor release during exercise? (1990) (15)
- Effects of renin—angiotensin system in mediating endothelin‐induced renal vasoconstriction: therapeutic implications (1994) (15)
- Atrial natriuretic peptide and blood pressure in a population-based sample. (1995) (15)
- Relationship between left ventricular wall stress and ANP gene expression during the evolution of rapid ventricular pacing‐induced heart failure in the dog (2000) (15)
- Exertional changes in circulating cardiac natriuretic peptides in patients with suggested coronary artery disease. (2006) (15)
- Tolvaptan (OPC-41061), a V2 vasopressin receptor antagonist, protects against the decline in renal function observed with loop diuretic therapy (2003) (15)
- Natriuretic peptides as regulators of myocardial structure and function: pathophysiologic and therapeutic implications. (2006) (15)
- Divergent effects of a designer natriuretic peptide CD-NP in the regulation of adipose tissue and metabolism (2017) (15)
- Atrial Natriuretic Peptide Genetic Variant rs 5065 and Risk for Cardiovascular Disease in the General Community A 9-Year Follow-Up Study (15)
- Plasma endothelin concentrations are increased in humans with congestive heart failure (1991) (15)
- Natriuretic Peptides in Cardiovascular Disease (1997) (14)
- Visualizing the basis for paracrine natriuretic peptide signaling in human heart. (2006) (14)
- Intact acute cardiorenal and humoral responsiveness following chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure (2006) (14)
- Atrial natriuretic factor. Is it physiologically important? (1990) (14)
- CRRL269: A Novel Particulate Guanylyl Cyclase A Receptor Peptide Activator for Acute Kidney Injury (2019) (14)
- Insights into natriuretic peptides in heart failure: An update (2008) (14)
- Oral brain natriuretic peptide: a novel strategy for chronic protein therapy for cardiovascular disease. (2007) (14)
- Attenuated natriuretic response to adrenomedullin in experimental heart failure. (2001) (13)
- Therapeutic potential for existing and novel forms of natriuretic peptides. (2006) (13)
- Pathophysiology of congestive heart failure: role of atrial natriuretic factor and therapeutic implications. (1991) (13)
- Hemodynamic and renal effects of acute and progressive nitric oxide synthesis inhibition in anesthetized dogs. (2001) (13)
- Role of atrial peptide system in renal and endocrine adaptation to hypotensive hemorrhage. (1988) (13)
- Left atrial size by planimetry is superior to M-mode diameter: biochemical calibration by atrial and brain natriuretic peptide. (2008) (13)
- Natriuretic Peptide Receptor-3 Gene (NPR3): Nonsynonymous Polymorphism Results in Significant Reduction in Protein Expression Because of Accelerated Degradation (2013) (12)
- Neurohumoral Modulation During Waon Therapy in Chronic Heart Failure - Subanalysis of Waon-CHF Study. (2017) (12)
- Vericiguat - Another Victory for Targeting Cyclic GMP in Heart Failure. (2020) (12)
- Prognostic value of multiple biomarkers in American Indians free of clinically overt cardiovascular disease (from the Strong Heart Study). (2009) (12)
- Distinct roles for renal particulate and soluble guanylyl cyclases in preserving renal function in experimental acute heart failure. (2007) (11)
- Long-Term Blood Pressure Lowering and cGMP Activating Actions of the Novel ANP Analogue MANP. (2020) (11)
- Bioactive Signaling in Next-Generation Pharmacotherapies for Heart Failure: A Review (2018) (11)
- Cyclic GMP modulating drugs in cardiovascular diseases: mechanism-based network pharmacology (2021) (10)
- Biologic role of atrial natriuretic factor clearance receptor in congestive heart failure. (1993) (10)
- Circulating Aldosterone and Natriuretic Peptides in the General CommunityNovelty and Significance (2015) (10)
- Ethical Issues in Cardiovascular Research Involving Humans (2009) (10)
- Natriuretic peptides and myocardial structure: insights from population genetics. (2007) (9)
- First-in-Human Study of MANP: A Novel ANP (Atrial Natriuretic Peptide) Analog in Human Hypertension (2021) (9)
- Decompensated heart failure: is there a role for the outpatient use of nesiritide? (2004) (9)
- Effect of plasma protein depletion on BNP-32 recovery. (2008) (9)
- Unrecognized myocardial infarction: the association with cardiopulmonary symptoms and mortality is mediated via echocardiographic abnormalities of global dysfunction instead of regional dysfunction: the Olmsted County Heart Function Study. (2006) (9)
- Cenderitide-Eluting Film for Potential Cardiac Patch Applications (2013) (9)
- Aldosterone, Hypertension, and Antihypertensive Therapy: Insights From a General Population (2018) (9)
- Contrast nephropathy, cardiology and the newer radiocontrast agents. (1988) (9)
- Effects of secretin on peritubular capillary physical factors and proximal fluid reabsorption in the rat. (1983) (9)
- A Functional Genetic Variant (N521D) in Natriuretic Peptide Receptor 3 Is Associated with Diastolic Dysfunction: The Prevalence of Asymptomatic Ventricular Dysfunction Study (2014) (9)
- Design, Synthesis, and Actions of an Innovative Bispecific Designer Peptide: NPA7 (2019) (9)
- Renal interstitial hydrostatic pressure and ANF in exaggerated natriuresis of the SHR. (1990) (9)
- A FIRST-IN-HUMAN TRIAL OF A NOVEL DESIGNER NATRIURETIC PEPTIDE ZD100 IN HUMAN HYPERTENSION (2016) (9)
- B-type natriuretic peptide: beyond a diagnostic. (2008) (9)
- Further attenuation of endothelium-dependent relaxation imparted by natriuretic peptide receptor antagonism. (1999) (9)
- Effects of bradykinin on renal interstitial pressures and proximal tubule reabsorption. (1984) (8)
- Angiotensin (1-12) in Humans With Normal Blood Pressure and Primary Hypertension. (2021) (8)
- The design, synthesis and cardiorenal actions of a new chimeric natriuretic peptide CD-NP (2003) (8)
- Discovery of a Novel Synthetic Natriuretic Peptide, CU-NP (2007) (8)
- Impaired Functional Status and Echocardiographic Abnormalities Signifying Global Dysfunction Enhance the Prognostic Significance of Previously Unrecognized Myocardial Infarction Detected by Electrocardiography (2007) (8)
- Prevention of Cardiorenal Fibrosis and Suppression of Proteinuria and Aldosterone Activation Following Experimental Myocardial Infarction with the Novel Natriuretic Peptide CD-NP (2009) (8)
- Atrial natriuretic factor: Physiologic actions and implications in congestive heart failure (2005) (8)
- Gene transfer of a novel vasoactive natriuretic peptide stimulates cGMP and lowers blood pressure in mice. (2004) (8)
- Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction. (2013) (8)
- Association Between Cardiac Natriuretic Peptides and Lipid Profile: a Systematic Review and Meta-Analysis (2019) (8)
- Regulation of Circulating Progenitor Cells in Left Ventricular Dysfunction (2010) (8)
- Effect of natriuretic peptides on cerebral artery blood flow in healthy volunteers (2015) (8)
- Activation of soluble guanylate cyclase and potassium channels contribute to relaxations to nitric oxide in smooth muscle derived from canine femoral veins. (1999) (8)
- Natriuretic peptide pathways in heart failure: further therapeutic possibilities (2022) (8)
- Early activation of deleterious molecular pathways in the kidney in experimental heart failure with atrial remodeling (2017) (8)
- In vivo Evaluation of Cenderitide-Eluting Stent (CES) II (2016) (8)
- Endothelin in neurohormonal activation in heart failure (2003) (8)
- Mineralocorticoid Escape by the Kidney But Not the Heart in Experimental Asymptomatic Left Ventricular Dysfunction (2007) (8)
- Newborn cardiorenal dynamics: a state of atrial natriuretic peptide unresponsiveness. (1991) (7)
- The relative value of the natriuretic peptides as markers for detecting abnormal ventricular structure and function (1996) (7)
- Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism. (1998) (7)
- Renal Outcomes in Patients with Systolic Heart Failure Treated With Sacubitril-Valsartan or Angiotensin Converting Enzyme Inhibitor/Angiotensin Receptor Blocker (2021) (7)
- Blood vessel physiology and pathophysiology. (1990) (7)
- Atrial natriuretic factor secretion: physiological regulation and implications in cardiovascular disease (1987) (7)
- Hemodynamic and plasma atrial natriuretic peptide responses to acute digitalis therapy in patients with normal and impaired left ventricular function (2002) (7)
- and Andre Contribution in Heart Failure Catalyzed Phosphotransfer in the Myocardium : Increased − (1999) (7)
- Natriuretic peptide infusion reduces myocardial injury during acute ischemia/reperfusion (2012) (7)
- In vitro evaluation of cenderitide-eluting stent I -an antirestenosis and proendothelization approach. (2014) (7)
- Proximal tubule response in aldosterone escape. (1989) (7)
- Arterial Remodeling in B-Type Natriuretic Peptide Knock-Out Females (2016) (7)
- The role of endothelium-derived relaxing factor in experimental congestive heart failure (1991) (7)
- Circulating paracrine and autocrine mechanisms in heart failure (1993) (6)
- C-Type Natriuretic Peptide (1996) (6)
- Intrarenal pressures during direct inhibition of sodium transport. (1992) (6)
- Targeting the kidney in acute decompensated heart failure: conventional diuretics and renal-acting vasodilators. (2008) (6)
- Discovery of small molecule guanylyl cyclase A receptor positive allosteric modulators (2021) (6)
- Natriuretic peptides and remodeling in heart failure. (2005) (6)
- High doses of ANP and BNP exacerbate lipolysis in humans and the lipolytic effect of BNP is associated with cardiac triglyceride content in pigs (2019) (6)
- Relaxing With C-Type Natriuretic Peptide, the Guanylyl Cyclase B Receptor, and Pericytes (2018) (6)
- Safety and Efficacy of an Orally Active Selective Endothelin-A Receptor Antagonist in Moderate-Severe Human Chronic Heart Failure (1999) (6)
- Nesiritide: new hope for acute heart failure syndromes? (2005) (6)
- Natriuretic peptides renal protective after all? (2011) (6)
- Cell Surface Protein Disulfide Isomerase Regulates Natriuretic Peptide Generation of Cyclic Guanosine Monophosphate (2014) (6)
- Targeting heme-oxidized soluble guanylate cyclase with BAY 58-2667 in experimental heart failure (2007) (6)
- Role of the natriuretic peptides in the cardiorenal and humoral actions of omapatrilat: Insights from experimental heart failure (2001) (6)
- The editor's roundtable: B-type natriuretic peptide. (2008) (6)
- Cenderitide (CD-NP), a novel peptide designed to activate both guanylyl cyclase B and A, activates the second messenger cGMP, suppresses aldosterone, and preserves GFR without reducing blood pressure in a proof-of-concept study in patients with chronic heart failure (2011) (5)
- The modulating actions of sulfonylurea on atrial natriuretic peptide release in experimental acute heart failure (2000) (5)
- Abstract 383: Heart-Kidney: Myocardial Infarction Mediates Renal Fibrosis and Activates Renal Molecular Remodeling in the Absence of Heart Failure (2007) (5)
- Potential future therapies: natriuretic peptides. (1999) (5)
- Can a cardiac peptide predict mortality in human hypertension? (2011) (5)
- Atrial Natriuretic Peptide, Heart Failure and the Heart as an Endocrine Organ. (2019) (5)
- DEFICIENCY OF THE CARDIORENAL PROTECTIVE HORMONE BNP IN EARLY STAGES OF HYPERTENSION: 2C.01 (2010) (5)
- C-type natriuretic peptide: the heart’s guardian angel (2019) (5)
- Endothelin at pathophysiologic concentrations is a potent renal vasoconstrictor resistant to atrial natriuretic factor (1990) (5)
- Dual inhibition of neutral endopeptidase (NEP) and angiotensin converting enzyme (ACE) suppresses atherogenesis and improves endothelial function in hypercholesterolemic rabbits (1996) (5)
- Atrial Fibrillation Natriuretic Peptide Levels in Atrial Fibrillation A Prospective Hormonal and Doppler-Echocardiographic Study (2000) (5)
- Specificity of C-type and atrial natriuretic peptides in human blood vessels (1996) (5)
- 787 Prognostic value and changes in renal function in patients admitted with acute heart failure - results from the EVEREST program (2008) (5)
- NT-proBNP is superior to BNP in the detection of left ventricular systolic dysfunction in the community (2004) (5)
- Response to Cardiac Resynchronization Therapy Improves Renal Function. Importance of Forward and Backward Failure. (2009) (5)
- Histopathology of familial versus nonfamilial dilated cardiomyopathy (1993) (5)
- Renal-endocrine adaptations to endogenous atrial natriuretic factor during tachycardia-induced reductions in renal perfusion pressure. (1990) (5)
- Natriuretic Peptides, Inflammation, and Sounding the Alarm. (2020) (4)
- B021: Hemodynamic and volume changes during intensive treatment (Rx) for resistant hypertension (ResHTN) (2000) (4)
- Cardiovascular actions of ET-B activation in vivo and modulation by receptor antagonism. (1998) (4)
- In-Vivo Evaluation of an In Situ Polymer Precipitation Delivery System for a Novel Natriuretic Peptide (2013) (4)
- Abstract 1484: New Insights into the Kidney-Heart Connection: Mild Renal Insufficiency Induces Cardiac Fibrosis and Diastolic Dysfunction Followed by Late Systolic Impairment (2008) (4)
- Neurohumoral and renal mechanisms in heart failure (1990) (4)
- A role for endothelin as a maeker of diffuse atherosclerosis in the human (1991) (4)
- Protein therapeutics for cardiovascular disease: it is all about delivery. (2012) (4)
- Cardiorenal Actions of TRV120027, a Novel, β-Arrestin-Biased Ligand at the Angiotensin II Type I Receptor, in Healthy and Heart Failure Canines: A Novel Therapeutic Strategy for Acute Heart Failure (2010) (4)
- Dissociation of renal interstitial hydrostatic pressure and natriuresis of atrial natriuretic factor. (1990) (4)
- Angiotensin II AT 1 receptor antagonism prevents detrimental renal actions of acute diuretic therapy in human heart failure (2003) (4)
- Atrial natriuretic factor inhibits hypertonic saline-mediated decreases in renal hemodynamics. (1990) (4)
- Elevation of circulating BNP in isolated diastolic dysfunction (1999) (3)
- CD-NP, A NOVEL PEPTIDE DESIGNED TO ACTIVATE BOTH GUANYLYL CYCLASE B AND A, ACTIVATES THE SECOND MESSENGER CGMP, SUPPRESSES ALDOSTERONE AND PRESERVES GFR WITHOUT REDUCING BLOOD PRESSURE IN A PROOF-OF-CONCEPT STUDY IN PATIENTS WITH CHRONIC HEART FAILURE (2011) (3)
- Acute Effects of Angiotensin II on Circulating Levels of Atrial Natriuretic Peptide in Conscious Dogs (1986) (3)
- Myocardial Aging, the Cardiac Atria, and BNP: What Does it All Mean? (2019) (3)
- Treatment of congestive heart failure in the elderly: emphasis on renal functional changes and impact of therapy (1997) (3)
- Atrial Natriuretic Peptide Effects on Cardiac Function In Vivo and in Vitro (1986) (3)
- The Anp genetic variant Rs5068 and circulating levels of natriuretic peptides in patients with chronic heart failure. (2014) (3)
- Abstract 371: Cardiorenal and Neurohumoral Actions of a Novel Designer Natriuretic Peptide, CU-NP, in Canine Experimental Heart Failure (2008) (3)
- Natriuretic Peptides and Blood Pressure Homeostasis: Implications for MANP, a Novel Guanylyl Cyclase a Receptor Activator for Hypertension (2022) (3)
- Circulating atrial natriuretic peptide genetic association study identifies a novel gene cluster associated with reduced NT-proANP, increased stroke and higher diastolic blood pressure (2015) (3)
- A new signal from B-type natriuretic peptide in ST-elevation myocardial infarction: what does it mean for B-type natriuretic peptide and innovative diagnostics? (2010) (3)
- Chapter 17 – Endothelin in Hypertension (2005) (3)
- ProBNP 1108 Processing and Degradation in Human Heart Failure (2014) (3)
- The Heart Failure Society of America in 2020: a vision for the future. (2012) (3)
- Modulating cGMP in heart failure (2007) (3)
- Continuing insights into the heart as an endocrine organ: adrenomedullin and cardiac fibroblasts. (2001) (3)
- BLAST-AHF: insights into biased AT1 ligands and heart failure. Beginning of the end or end of the beginning? (2017) (3)
- UTILITY OF DOPPLER MYOCARDIAL IMAGING, CARDIAC BIOMARKERS AND CLONAL IMMUNOGLOBULIN GENES TO ASSESS LEFT VENTRICULAR PERFORMANCE AND STRATIFY RISK FOLLOWING PERIPHERAL BLOOD STEM CELL TRANSPLANTATION IN PATIENTS WITH SYSTEMIC LIGHT CHAIN AMYLOIDOSIS (AL). (2010) (3)
- Abstract 2166: Design, Synthesis and Unique Biological Actions of CD-NP: A Novel CNP-like Chimeric Natriuretic Peptide (2006) (3)
- Designer natriuretic peptides for heart failure: advanced in clinical development (2011) (3)
- Long-Term Structural and Functional Myocardial Adaptations in Healthy Living Kidney Donors: A Pilot Study (2015) (3)
- V2 receptor antagonism with tolvaptan in heart failure (2007) (3)
- Cardiac Versus Renal Response to Volume Expansion in Preclinical Systolic Dysfunction With PDEV Inhibition and BNP (2019) (3)
- Anti-Remodeling Effects of Chronic Phosphodiesterase-Type-5 Inhibition Are Dependent on Impaired cGMP-Dependent Protein Kinase Signaling (2009) (3)
- Sildenafil, a phosphodiesterase V inhibitor potentiates the renal actions of subcutaneously administered BNP without adverse hemodynamic effects in experimental overt heart failure (2004) (3)
- Co-activation of soluble and particulate guanylate cyclase by BAY 58-2667 and BNP enhances cardiorenal function in experimental heart failure (2005) (3)
- Hypertension Long-Term Cardiac proB-Type Natriuretic Peptide Gene Delivery Prevents the Development of Hypertensive Heart Disease in Spontaneously Hypertensive Rats (2011) (3)
- Prognostic Value of Urinary and Plasma C-Type Natriuretic Peptide in Acute Decompensated Heart Failure. (2021) (2)
- Abstract 1889: Cardiac Resynchronization Therapy With Biventricular Pacing Improves Renal Function in Heart Failure Patients With Reduced Glomerular Filtration Rate (2007) (2)
- The Role of Endothelin in Congestive Heart Failure (1995) (2)
- M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics (2013) (2)
- Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics (2013) (2)
- Differential Biological Actions and Assay Detection of Altered Forms of BNP In Vitro (2006) (2)
- Intra-Renal Infusion of BNP in Experimental Heart Failure: A Novel Strategy To Maximize the Renal Enhancing Actions of BNP While Minimizing Arterial Hypotension (2006) (2)
- The Non-Failing Human Heart Secretes ProBNP 1-108 (2010) (2)
- Sustained delivery of a novel natriuretic peptide for three weeks with in situ polymer precipitation delivery system (2012) (2)
- Abstract 15205: MANP: A Novel ANP Analog for Hypertension Associated With Obesity and Metabolic Syndrome (2020) (2)
- Inhibition by calcium antagonism of circulating and renal endothelin in experimental congestive heart failure. (1996) (2)
- The effect of atrial natriuretic factor (ANF) on renal hemodynamics and renin secretion in the non-filtering dog kidney (1985) (2)
- CRRL269. (2019) (2)
- Abstract 3272: B-Type Natriuretic Peptide Single Nucleotide Polymorphism rs198389 Impacts Test Characteristics of Common Assays (2009) (2)
- Circulating Levels of Atrial Natriuretic Factor Are Elevated in Rats with Experimental High-Output Heart Failure (1986) (2)
- Mortality in end stage heart failure is associated with paradoxically low NT-pro BNP and BNP levels: “natriuretic peptide exhaustion”? (2004) (2)
- Effect of endogenous natriuretic peptide system on ventricular and coronary function in failing heart. (1997) (2)
- Cenderitide, a novel dual GC-A and GC-B receptor activator, is a potent chronic cardiorenal fibroinhibiting peptide which suppresses aldosterone and reduces proteinuria in models of ardiorenal fibrosis (2011) (2)
- Renal Cyclic GMP Stimulating Actions of a Novel Chimeric Natriuretic Peptide CD-NP in Isolated Glomeruli: Evidence for NPR-A Activation (2008) (2)
- Biological Actions of a Novel Oral Human BNP in an Experimental Model of Acute Hypertension (2006) (2)
- PRECLINICAL DIASTOLIC DYSFUNCTION: THE KIDNEY-HEART CONNECTION (2010) (2)
- MANP (Mutant Atrial Natriuretic Peptide) Activation of the cGMP (3',5', Cyclic Guanosine Monophosphate) Inhibits Aldosterone via PDE2 (Phosphodiesterase 2) and Cytochrome p450 Family 11 Subfamily b Member 2 in H295R Cells and in Mice. (2022) (2)
- Acute NEP/ACE inhibition by omapatrilat is superior to ace inhibition alone in mediating favorable cardiorenal and humoral actions in mild heart failure (1999) (2)
- Endothelium-dependent vasodilation during acute rejection in dogs. (2004) (2)
- Dose-related antihypertensive efficacy of omapatrilat, a vasopeptidase inhibitor, in models of normal and low renin hypertension (1999) (2)
- ZD100: a novel pGC-A activator for the treatment of resistant hypertension: in vitro resistance to neprilysin degradation (2016) (2)
- Pro–B-Type Natriuretic Peptide1–108 Circulates in the General Community (2011) (2)
- Heart failure: Furosemide—to DOSE or not to DOSE, that is the question (2011) (2)
- Congestive heart failure: pharmacological agents and the potential of B-type natriuretic Peptide. (2005) (2)
- Abstract 14201: ANX-042, a Novel Natriuretic Peptide (NP), is Safe and Stimulates Cyclic Guanosine Monophosphate (cGMP) in Healthy Volunteers (2013) (2)
- Cofilin-1: A Possible New Biomarker for Human Heart Failure (2007) (2)
- Plasma neurohormonal changes in response to cardiac resynchronization therapy in patients with congestive heart failure (2003) (2)
- MANP (M-Atrial Natriuretic Peptide) Reduces Blood Pressure and Furosemide-Induced Increase in Aldosterone in Hypertension (2022) (2)
- The new designer peptide CD-NP unloads the heart, suppresses renin and is natriuretic in vivo (2003) (2)
- Dual inhibition of neutral endopeptidase and angiotensin converting enzyme delays the progression of experimental heart failure (1996) (2)
- Dipeptidyl Peptidase IV Inhibition with Sitagliptin Augments cGMP-Activating and Hypotensive Properties of B-Type Natriuretic Peptide (2008) (2)
- Pilot study assessing dose and tolerability of BNP (nesiritide) infusion post anterior myocardial infarction to prevent adverse left ventricular remodeling and heart failure (2004) (2)
- Renal Mechanisms of Action of a Novel Designer Natriuretic Peptide, CU-NP (2008) (2)
- Human Angiotensin‐(1‐12) [Ang‐(1‐12)] is a Hypertension and Cardiac Disease Biomarker (2020) (2)
- Activation of endothelin during arterial thrombosis and thrombolysis (1991) (2)
- The effect of dietary sodium on the pressor and endocrine action of endothelin (1991) (2)
- Atrial, ventricular, and plasma atrial natriuretic factor during the evolution of congestive heart failure (1991) (1)
- Chronic natriuretic peptide protein therapeutics (2013) (1)
- Abstract 12651: Atrium Fibrosis and Inflammation: Impaired Atrial Natriuretic Peptide System in Experimental Heart Failure (2014) (1)
- Characterization of anp genetic variant rs5068 in chronic heart failure patients (2014) (1)
- Urinary Angiotensinogen is Increased in Human Heart Failure (2015) (1)
- Myocardial and circulating endothelin is activated prior to the reninangiotensin-aldosterone system during the transition from compensated to overt congestive heart failure (1999) (1)
- Abstract 14880: Cardiorenal Response to Acute Volume Loading in Human Preclinical Diastolic Dysfunction (Stage B Heart Failure) After 12 weeks of Chronic SQ BNP Administration (2013) (1)
- Coronary Endothelial Function in Health and Disease (2012) (1)
- cGMP enhancing strategies for acute and chronic heart failure (2005) (1)
- Co-Targeting of the V2 Receptor with Tolvaptan and the Natriuretic Peptide A-Receptor with B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal Function: A Novel Physiologic Approach to Sodium and Water Retention in Experimental Heart Failure (2006) (1)
- Contrasting Activation of BNP in Left Ventricular Remodeling due to Primary Volume Overload or Dysfunction (1998) (1)
- Human Platelet-Rich and Platelet-Poor Plasma Atrial Natriuretic Peptide Levels During Dehydration (1986) (1)
- Continuous Renal Interstitial Hydrostatic Pressure Dynamics During Atrial Natriuretic Peptide Administration (1986) (1)
- Abstract 12951: Human C-Type Natriuretic Peptide-53: A Distinct Molecular Form With in vitro and in vivo Biological Actions Through cGMP Generation (2014) (1)
- Natriuretic Peptides in Heart Failure: Pathophysiologic and Therapeutic Implications (2020) (1)
- Proteomic Biomarkers of Sacubitril/Valsartan Treatment Response in Heart Failure With Preserved Ejection Fraction: Molecular Insights Into Sex Differences. (2022) (1)
- Morphologic localization of endothelin immunoreactivity within the kidney (1990) (1)
- Atrial fibrillation is associated with elevated N-ANP levels independently of atrial size, ventricular function and endothelin level (1998) (1)
- ZD100 in a genetic model of essential hypertension and characterization of the role of the C-terminus of this novel designer peptide (2016) (1)
- Chronic subcutaneous administration of BNP in human heart failure for eight weeks: a pilot study to establish safety and lack of tolerance (2003) (1)
- Extracellular Matrix Protein Interactions with Natriuretic Peptide and Integrin Receptors in Human Cardiac Fibroblasts (2009) (1)
- NPA7, A FIRST IN CLASS DUAL RECEPTOR ACTIVATOR WITH CARDIO-RENOPROTECTIVE PROPERTIES IN VIVO (2017) (1)
- 776-4 Intact cNOS-NO-cGMP Pathway in the Failing Human Heart (1995) (1)
- Abstract 8754: cGMP Enhancing Therapy Improves LV Diastolic Distensibility by Phosphorylating Titin (2010) (1)
- Effect of Ethnicity on Plasma Levels of proBNP, BNP and NTproBNP in Subjects at Risk for Cardiovascular Disease (2012) (1)
- The cardiac peptide BNP is superior to ANP and the renally derived peptide urodilatin in enhancing renal function in overt experimental congestive heart failure (2003) (1)
- Temporal alteration in endothelium-dependent responses of canine coronary arteries in congestive heart failure (1991) (1)
- Characterization of circulating and urinary c-type natriuretic peptide molecular forms and their cyclic GMP activating actions in humans: insights into biology and therapeutics (2013) (1)
- Cardiorenal actions of the new heme-independent direct soluble guanylate cyclase activator BAY 58-2667 in experimental congestive heart failure (2003) (1)
- N010: Determinants of natriuretic peptide levels in an urban multi-ethnic hypertensive population (2000) (1)
- Abstract 1485: Tissue Specific Activation of cGMP by an Alternatively Spliced Form of BNP (2008) (1)
- Anti-Proliferative Mechanisms of BNP in Cultured Human Cardiac Fibroblasts: Role for the Clearance Receptor, p21 and Cyclin D1 (2006) (1)
- A Role for Calcium and Radiocontrast-Induced Reductions in Renal Hemodynamics (1985) (1)
- Increased nephrogenous endothelin generation during radiocontrast administration (1991) (1)
- A new natriuretic peptide present in canine plasma and heart (1998) (1)
- Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community (2009) (1)
- Abstract 2495: Pharmacodynamic Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide (2007) (1)
- Atrial natriuretic factor release is augmented by leg elevation in human subjects with congestive heart failure (1991) (1)
- Presence and distribution of vascular wall adrenomedullin in experimental atherosclerosis (1996) (1)
- ZD100 a Novel Particulate-Guanylyl-Cyclase A Receptor Activator in Human Resistant “Like” Hypertension—A First in Human Study (2016) (1)
- B-Type Natriuretic Peptide Predicts the Outcome of Cardiac Resynchronization Therapy (2012) (1)
- MANP: A Novel Designer Natriuretic Peptide for Cardiometabolic Disease (2012) (1)
- AlbuBNP (Cardeva), a Novel Recombinant Human B-Type Natriuretic Peptide Serum Albumin Fusion Protein Has Prolonged Renal Enhancing Properties When Compared to Human BNP (2007) (1)
- Corin expression in specific human cardiac endothelial cells and cardiac fibroblasts (2003) (1)
- Plasma BNP to screen for systolic dysfunction in the community: importance of using age- and sex-specific partition values (2002) (1)
- Coadministration of the Vasopressin-2 Receptor Antagonist Tolvaptan and B-Type Natriuretic Peptide Enhances Water and Sodium Excretion without Adversely Affecting Renal or Neurohumoral Function in Experimental Congestive Heart Failure (2007) (1)
- Abstract 15143: ZD100: BP Lowering, Renal Enhancing and Aldosterone Suppressing Properties via pGC-A in Human Resistant “Like” Hypertension - A First in Human Study (2016) (1)
- Renal actions of the cancion® Cardiac Recovery System in severe experimental heart failure (2004) (1)
- Receptor guanylyl cyclase (RGC) family (version 2019.4) in the IUPHAR/BPS Guide to Pharmacology Database (2019) (1)
- The impact of parturition and severe preeclampsia on gestational plasma endothelin (ET-1) concentrations (1994) (1)
- Correction: Discovery of O-glycans on atrial natriuretic peptide (ANP) that affect both its proteolytic degradation and potency at its cognate receptor. (2019) (1)
- Novel ProteIn TherapeutiCs for Chronic Systolic HEart Failure: Chronic Subcutaneous BNP Administration (NICE BNP) (2010) (1)
- Receptor guanylyl cyclase (RGC) family (version 2020.3) in the IUPHAR/BPS Guide to Pharmacology Database (2020) (1)
- Pro-B-Type natriuretic peptide: a novel, specific biomarker for detection of left ventricular dysfunction in the general community (2009) (1)
- Dystrophin analysis inidiopathic dilated cardiomyopathy (1993) (1)
- Neprilysin in HFrEF (2020) (1)
- P6528Cardiorenal protection by subcutaneous cenderitide in experimental heart failure: a novel and safe therapeutic for humans with LVAD support (2018) (1)
- Pathophysiology of the cardiorenal syndrome in acute heart failure (2005) (1)
- Progressive decline in circulating CNP with aging is associated with progressive cardiac fibrosis and myocardial impairment (2009) (1)
- Pharmacokinetic and pharmacodynamic study of a novel chimeric natriuretic peptide, CD-NP, in the normal dog (2007) (1)
- Association of NPPA rs5065 Genetic Variant With Increased Cardiovascular Risk in the General USA Population (2010) (1)
- Aldosterone levels, atrial natriuretic peptide and resistant hypertension in the general community (2016) (1)
- Dendroaspis natriuretic peptide-like immunoreactivity is present in human plasma and is elevated in human heart failure (1998) (1)
- 979-37 Endothelin-1 at Pathophysiological Concentrations Induces Coronary Vasoconstriction via the ET-A Receptors (1995) (1)
- Abstract 12893: Design and cGMP-Generating Actions of a Novel Selective and Non-Selective Particulate Guanylyl Cyclase B Activator Targeting Cardiorenal Fibrotic Remodeling (2016) (1)
- Systemic arterial hypertension in the immediate postoperative period of liver transplantation: Role of endothelin? (1990) (1)
- P4450A cardio-metabolic phenotype in carriers of NPPA (rs5086) and NPPB (rs198389) gene variants in the general population: the dominant role of ANP (2018) (1)
- Aged Mediated Cardiac Fibrosis and Diastolic Impairment Is Associated with a Reduction in the Collagen Degrading Pathway and an Imbalance between the Natriuretic Peptide and the Renin-Angiotensin-Aldosterone Systems (2013) (1)
- P-536: Utility of BNP as a biomarker for assessing functional class during therapy in a heart failure specialty clinic (2001) (1)
- P6342Subcutaneous delivery of NPA7, first-in-class novel bispecific designer peptide: enhances cardiorenal function and suppresses renin and aldosterone in vivo and in vitro (2019) (1)
- Designer natriuretic peptides: Innovative peptide therapeutics for cardiovascular disease (2012) (1)
- N011: Differential cardiovascular actions of omapatrilat versus ace inhibitor and diuretics in early left ventricular dysfunction (2000) (1)
- 575 Cenderitide: A Novel Designer Natriuretic Peptide Therapeutic Strategy for the Prevention of Adverse Cardiac Fibrosis and Diastolic Dysfunction Induced by Mild Renal Insufficiency (2012) (1)
- Renal response to synthetic atrial natriuretic factor in acute low output failure (1985) (1)
- Controlling the flood gates: vaptans, furosemide and the quest for a renal protective diuresis. (2011) (1)
- Circulating Pronatriuretic Peptide Convertase Corin Is Present in Normal and Heart Failure Patients and Processes proBNP1-108 in Human Blood (2010) (1)
- The Endocrine Heart (2016) (1)
- The B-Type Natriuretic Peptide T–381C Polymorphism Is Associated with Increased BNP Plasma Immunoreactivity and Higher Prevalence of Type 2 Diabetes Mellitus and Atrial Fibrillation (2008) (1)
- Renal resistance to BNP in severe experimental heart failure is overcome with high dose Nesirtide (2004) (1)
- Abstract 1412: A Novel Designer Natriuretic and Diuretic Peptide Based Upon an Alternatively Spliced BNP Without Vascular Vasodilatory Actions (2006) (1)
- Abstract 3385: Cyclic GMP Activating Actions and Assay Detection of Altered Forms of BNP in vitro (2006) (1)
- 528: Endothelin-1 and BNP Plasma Levels Predict Survival in Patients with Pulmonary Arterial Hypertension (2009) (1)
- A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts (2009) (1)
- Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of B-type Natriuretic Peptide For the Preservation of Left Ventricular Function Post Anterior Myocardial Infarction (2013) (1)
- AlbuBNP, a Recombinant Human B-Type Natriuretic Peptide and Serum Albumin Fusion Hormone Has Prolonged Natriuretic, Glomerular Filtration Rate Enhancing and Aldosterone Inhibiting Properties (2006) (1)
- Specific roles for the natriuretic peptides as biomarkers in coronary artery disease and left ventricular dysfunction (2004) (1)
- ANP, BNP and CNP: Physiology and Pharmacology of the Cardiorenal Axis (2009) (1)
- Regulation of Vasomotion (2005) (1)
- 995-18 Coronary Endothelial Dysfunction in Patients with Normal Coronary Angiography and Abnormal Functional Tests (1995) (1)
- Response to Letter Regarding Article, “Serial Biomarker Measurements in Ambulatory Patients With Chronic Heart Failure: The Importance of Change Over Time” (2008) (1)
- Erratum: Urinary endothelin and renal vasoconstriction with cyclosporine or FK506 after liver transplantation (Kidney International 47: (1426-1433)) (1995) (1)
- 1160-167 Defining the acute cardiorenal response to high dose nesiritide in severe experimental congestive heart failure (2004) (1)
- Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model (2011) (1)
- Purification, characterization, and preliminary serial crystallography diffraction advances structure determination of full-length human particulate guanylyl cyclase A receptor (2022) (1)
- Working Group on Emergency Department Management of Acute Heart Failure Research Challenges and Opportunities (1)
- Early initiation of ET-A receptor antagonism improves cardiovascular hemodynamics in severe but not mild experimental CHF (1998) (1)
- Engineered Mutation of Human B-Type Natriuretic Peptide To Preserve Renal Perfusion Pressure (2008) (0)
- Comparison of the Effects of Pentaerythritol Tetranitrate and Nitroglycerin on Endothelium- Dependent Vasorelaxation in Male Volunteers (2003) (0)
- The effect of variations in dietary sodium on plasma adrenomedullin (ADM) levels in cardiac transplant recipients (1996) (0)
- Predictors of B-type and atrial natriuretic peptide in a patient population with congestive heart failure and intraventricular conduction delay (2003) (0)
- in renal hemodynamics (1985) (0)
- A novel designer natriuretic peptide integrating human C‐type natriuretic peptide, atrial natriuretic peptide, and B‐type natriuretic peptide (2009) (0)
- Incremental Burnden of CRI in the General Population and Added Predictive Power of GFR Together with BNP and NT-proBNP in Detection of Altered Ventricular Structure and Function (2008) (0)
- Acute heart failure: A “relative brain natriuretic peptide deficiency state”. Functional and therapeutic implications (1996) (0)
- Chapter 18 – Alterations in Renal Function in Heart Failure (2011) (0)
- Discovery of vasonatrin peptide (1994) (0)
- 039 - Discovery of Novel Small Molecule Activators and Modulators of the Guanylyl Cyclase a Receptor Pathway by High Throughput Screening (2017) (0)
- Regional Comparison of Baseline Therapy in Patients Hospitalized for Acute Heart Failure with Systolic Dysfunction (2007) (0)
- Chronic uninephrectomy in a large animal is characterized by preservation of cardiovascular homeostasis but with cardiorenal activation of the cGMP system together with atrial fibrosis (2013) (0)
- Immunoelectron microscopic detection of C-type natriuretic peptide in normal human atrial tissue (1993) (0)
- Potent cardiac unloading actions of a new synthetic natriuretic peptide (BD-NP) in experimental severe congestive heart failure (2002) (0)
- 607 Cardiac unloading and GFR enhancing properties of a designer peptide BD‐NP are superior to human BNP in vivo (2005) (0)
- Mineralocorticoid excess does not result in Sodium retention but in cardiac fibrosis in experimental asymptomatic left ventricular dysfunction (2003) (0)
- Abstract P006: Systematic Identification Of Metabolites Associated With Manp, A Novel Anp Analog, In Human Hypertension With Metabolic Syndrome (2022) (0)
- Erratum: Designer natriuretic peptides (J Investigat Med. (2009) 57 (18-21)). (2009) (0)
- P1264Cardioprotective effects of a novel designer C-type natriuretic peptide-based therapeutic, C53, for the prevention of post-myocardial infarction heart failure (2018) (0)
- M-Atrial Natriuretic Peptide and Nitroglycerin in a Model of Acute Hypertensive Heart Failure: A Comparison of Two cGMP Therapeutics (2011) (0)
- Abstract 17940: PDEV Inhibition + BNP Administration Enhanced the Cardiac but not the Renal Response to Acute Volume Overload in Human Preclinical Diastolic Dysfunction as Compared to PDEV Inhibition Alone (2014) (0)
- Abstract 13164: Differential Expression of Myocardial Pronatriuretic Peptide Convertases Furin and Corin in Experimental Heart Failure (2010) (0)
- SUSTAINED ACTING ATRIAL NATRIURETIC PEPTIDE: A NOVEL THERAPEUTIC IN A CANINE MODEL OF ACUTE HYPERTENSION AND LEFT VENTRICULAR DYSFUNCTION INDUCED BY ANGIOTENSION II (2010) (0)
- Bradykinin-induced changes in sodium excretion with control of renal interstitial pressure and prostaglandin synthesis (1981) (0)
- C-Reactive Protein : A New Adjunct to Predicting Cardiovascular Risk (2003) (0)
- The novel dual GC-A and GC-B designer natriuretic peptide, cenderitide (CD-NP), enhances the renal actions of furosemide in a model of severe heart failure (2011) (0)
- The Cardiorenal Syndrome : A Clinician's Guide to Pathophysiology and Management (2011) (0)
- PS 16-01 INSULIN AND GLUCOSE INDUCE NATRIURETIC PEPTIDE CLEARANCE RECEPTOR IN HUMAN ADIPOCYTES: A METABOLIC LINK WITH THE CARDIAC NATRIURETIC PATHWAY (2016) (0)
- Abstract 15611: Mild Renal Dysfunction Induces Cardiomyocyte Apoptosis and Cardiac Fibrosis: Prevented by Chronic Subcutaneous Cenderitide (2011) (0)
- Acute and Chronic Subcutaneous Administration of ZD100, a Novel pGC-A/cGMP Peptide Activator, Demonstrates Robust Antihypertensive Efficacy in Rodents (2019) (0)
- Increased endothelin at rest and during exercise in older hypertensive men (1991) (0)
- IMPACT OF ETHNICITY ON PROBNP1-108, BNP1-32 AND NTPROBNP1-76 LEVELS IN HYPERTENSIVE CAUCASIANS AND HISPANICS (2011) (0)
- 482 Anti-fibrotic property of brain natriuretic peptide in cardiac fibroblasts: cross-talk action with endothelin-1 and tumor necrosis factor on the induction of matrix metalloproteinases (2003) (0)
- Abstract 15212: Npa7, a First in Class Dual Receptor Activator With Renoprotective Properties (2016) (0)
- Abstract 15362: Elevated Systemic and Renal cGMP May Contribute to Preserved Cardiovascular Homeostasis in a Large Animal Model of Mild Renal Insufficiency Induced by Uninephrectomy: Relevance to Renal Donation and Cardioprotective Strategies (2012) (0)
- Chronic Treatment with Novel Insulin Secreting Peptide and its Effect on Cardio-Metabolic Profiling in an Experimental Model of Diabetic Cardio-Nephropathy (2014) (0)
- Chronic angiotensin II (AT1) receptor antagonism selectively enhances renal cGMP production with improved renal function in experimental overt congestive heart failure (2002) (0)
- 175 Chronic oral ET‐A receptor antagonism in experimental heart failure activates the renin‐angiotensin system resulting in persistent sodium retention (2003) (0)
- M-Atrial Natriuretic Peptide: A Novel Designer Natriuretic Peptide with Sustained Blood Pressure Lowering and Cyclic GMP Activating Actions in a Chronic Canine Model of Angiotensin II-Induced Hypertension (2014) (0)
- Abstract 2493: Design, Synthesis, and Pharmacologic Actions of a Novel Designer Natriuretic Peptide: CU-NP (2007) (0)
- A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel designer natriuretic peptide in an experimental model of myocardial infarction (2013) (0)
- Therapeutic Insights for Heart Failure: In Vivo Comparison Between a Guanylyl Cyclase Receptor A and a Novel Guanylyl Cyclase Receptor B Activator (2015) (0)
- The novel dual GCA and GCB designer natriuretic peptide , cenderitide ( CD-NP ) , enhances the renal actions of furosemide in a model of severe heart failure (2011) (0)
- DNP-an endothelial cell derived member of the natriuretic peptide family (2000) (0)
- Abstract 5262: Progressive Decline in C-Type Natriuretic Peptide With Aging is Associated With Cardiorenal Fibrosis, Myocardial Dysfunction and Proteinuria (2009) (0)
- D endroaspis natriuretic peptide relaxes isolated human arteries and veins (2002) (0)
- Is Cystatin C a Biomarker for Proatherogenic Factors and Early Renal Insufficiency in Human Coronary Artery Disease without Systolic Dysfunction (2008) (0)
- Chronic oral endothelin-A receptor antagonism activates the renin-angiotensin-system with persisting sodium retention in experimental heart failure (2003) (0)
- Editorial Board (2010) (0)
- Dyssynchrony and Fibrosis in a Canine Model of Hypertension Correlates with Aldosterone-Mediated Depletion in Circulating Progenitor Cell Counts (2008) (0)
- The Natriuretic Peptide Receptors NPR-A and NPR-B Are Differentially Regulation by Extracellular Matrix Proteins (2011) (0)
- P615Circulating corin in the general community: link to gender and metabolic dysfunction (2018) (0)
- Effects of long-term proBNP cardiac gene delivery in experimental hypertensive heart disease (2011) (0)
- Abstract 15392: Therapeutic Benefit of a Novel GC-B Activator on Cardiac Remodeling in Experimental Chronic Kidney Disease (2017) (0)
- NPA7: A NOVEL DESIGNED BISPECIFIC PEPTIDE THAT PROTECTS HUMAN CARDIOMYOCYTES AGAINST OXIDATIVE STRESS THROUGH GC-A/MAS RECEPTORS (2023) (0)
- All Three NP Pre/Prohormones are Processed in Normal Human Blood Into Biologically Active Mature Peptides (2012) (0)
- Myocardial Specific BNP Gene-Delivery Improves Diastolic Function and Ventricular Structure in Spontaneous Hypertensive Rodents (2010) (0)
- Editorial board (1993) (0)
- 562 Effect of cardiac resynchronization therapy on neurohormonal activation in patients with congestive heart failure (2003) (0)
- Circulating aldosterone in the general community: biomarker, mediator of cardiorenal and metabolic disease and inhibitor of the natriuretic peptide system (2014) (0)
- The ANP Genetic Variant rs5068 Is Associated with Higher Circulating Concentrations of Natriuretic Peptides in Patients with Chronic Heart Failure (2013) (0)
- Genetic variants of ANP and cardiometabolic protection: from populations to novel therapeutics (2013) (0)
- Cardiorenal actions of the novel direct soluble guanylate cyclase stimulator BAY 41–2272 in experimental congestive heart failure in comparison to nitroglycerin (2003) (0)
- Potential Renal Biomarkers in Experimental Left Ventricular Dysfunction (2010) (0)
- Pro-atrial natriuretic peptide1-126 is processed in the human circulation to a mature GC-A activating peptide with therapeutic potential in heart failure (2013) (0)
- OR-48: BNP enhances renal actions of lasix and suppresses lasix-induced aldosterone activation in experimental heart failure (2003) (0)
- Inappropriate renal hemodynamic response to hypertonic saline in dogs with experimental acute congestive heart failure (1990) (0)
- Only Large Changes (>80%) in BNP Modify Risk in Patients with Chronic Heart Failure (2007) (0)
- Circulating cGMP Levels in the General Population: Relationship with Cardiovascular and Renal Diseases (2015) (0)
- Therapeutic actions of a novel natriuretic peptide in experimental overt congestive heart failure (1999) (0)
- Abstract 10128: NT-pro C-type Natriuretic Peptide is a Novel Urinary Biomarker with Prognostic Value in Hospitalized Heart Failure Patients Independent of Glomerular Filtration Rate (2011) (0)
- 40: Changes In the Neurohormonal Profile of Patients Hospitalized for Acute Heart Failure Syndromes During the Early Post-Discharge Period According to Early, Late, or No Heart Failure Re-Hospitalization or Mortality Events: Analysis From the EVEREST Trials (2010) (0)
- Cardiovascular Reflexes and Hormones (2006) (0)
- Potent cardiorenal actions in experimental heart failure with dual activation of soluble and particulate guanylate cyclases by bay 58-2667 and B-type natriuretic peptide: a novel therapeutic strategy (2004) (0)
- 404 Chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure does not result in the development of tolerance to exogenous BNP (2003) (0)
- Increased N-terminal Chromogranin A release is associated with cardiac reperfusion in pigs (2012) (0)
- Cardiac Natriuretic Peptide And Cgmp Impairment In Human Decompensated Heart Failure: Employing A Novel Ex Vivo Natriuretic Peptide/GC-A/cGMP Potency Assay To Evaluate Natriuretic Peptide Therapeutic Capacity (2022) (0)
- Localization of atrial natriuretic peptide in normal human atrial tissue by immunoelectron microscopy (1993) (0)
- Abstract 3018: A Dual Inhibitor of Neprilysin and Ligand of the Natriuretic Peptide Receptor C Augments the Endogenous Natriuretic Peptide System and Has Favorable Cardiorenal Actions in Experimental Heart Failure (2009) (0)
- PROBNP GENE DELIVERY PREVENTS HYPERTENSIVE HEART DISEASE IN SPONTANEOUSLY HYPERTENSIVE RATS: 2B.04 (2011) (0)
- The Newly Designed Dual Guanylyl Cyclase A and B Activator, CU-NP, Elicits Fibro-Suppressing and Favorable Cardiorenal Hemodynamic Actions (2012) (0)
- Aldosterone: Marker and Predictor of Cardiorenal and Metabolic Disease in the General Community (2014) (0)
- Abstract 14354: Cardiorenal Actions of the Designer Natriuretic Peptide, Cenderitide, in a Severe Heart Failure Model Treated With Furosemide Bolus (2011) (0)
- A Novel Chimeric Peptide, ANG1-7/BNP, with Dual In Vitro and In Vivo Actions through the Natriuretic Peptide Receptor and Mas Receptor Systems (2013) (0)
- In Vitro and In Vivo Actions of a Novel ANP Genetic Variant: Unique Actions on Human Endothelial Cells (2011) (0)
- Circulating Atrial Natriuretic Peptide Genetic Association Study Identifies a Novel Gene Cluster Associated with Reduced NT-proANP, Increased Stroke and Higher Diastolic Blood Pressure (2015) (0)
- The Guanylyl Cyclase Receptor B and Cyclic GMP Activating Actions of a Unique Molecular Form of C-Type Natriuretic Peptide In Vitro and In Vivo (2014) (0)
- ROLE OF NITRIC OXIDE IN THE CONTROL OF BASAL HEMODYNAMICS. AUTHOR'S REPLIES (1992) (0)
- Atrial Natriuretic Peptide May Be Superior to B-Type Natriuretic Peptide in Monitoring Cardiac Resynchronization Therapy (2006) (0)
- The Cardiac Natriuretic Peptide System: Linking the Heart and Kidney in Cardiorenal Homeostasis and Therapeutics (2018) (0)
- Plasma Aldosterone, ANP, Hypertension and Stage A and B Heart Failure in the General Community (2016) (0)
- P-378: C-type natriuretic peptide in the cardiac ventricle in mice (2001) (0)
- New Insights into the Effect of Mineralocorticoids on Circulating Progenitor Cell Counts in Canine Models of Cardiovascular Disease: The Case for Accelerated Senescence (2008) (0)
- RAA in CHF. (1979) (0)
- Abstract 620: The Cardiac Hormone BNP Inhibits Cardiac Fibroblast Proliferation via the Clearance Receptor and Modulation of p21 and Cyclin D1 (2006) (0)
- Cardiorenal Effects of Long‐Term Phosphodiesterase V Inhibition in Pre–Heart Failure (2022) (0)
- C-TYPE NATRIRUETIC PEPTIDE DEFICIENCY IN HUMAN OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY (2023) (0)
- Differential Cardiac versus Renal Response to Acute Volume Overload in Human Preclinical Systolic Dysfunction and Renal Dysfunction with the Combination of PDEV Inhibition and BNP Administration (2014) (0)
- B-type natriuretic peptide single nucleotide polymorphism rs198389 and survival in the general community (2009) (0)
- Reply: The Role of miRNAs and lncRNAs in ANP Production Downregulation in Heart Failure. (2020) (0)
- Right Atrial Inversion Causes Increased ANF Secretion During Cardiopulmonary Bypass (1989) (0)
- Abstract 11341: The Newly Designed Dual Guanylyl Cyclase A and B Activator, CU-NP, Elicits Favorable Cardiorenal Hemodynamic Actions without Hypotension and Activates the Second Messenger cGMP in Isolated Cardiac Fibroblasts and Glomeruli (2012) (0)
- Neurohumoral Changes with Cardiac Resynchronization Therapy in Patients with Congestive Heart Failure (2003) (0)
- Particulate and soluble guanylyl cyclase stimulation in the treatment of heart failure (2003) (0)
- kidney-heart connection cardiac apoptosis, fibrosis, and diastolic dysfunction: a Experimental mild renal insufficiency mediates early (2012) (0)
- Pathophysiology: Discussion II (1993) (0)
- 1087-108 Enhanced instability of membranous type 1 matrix metalloproteinase in response to mechanical loading in left ventricular myocardium (2004) (0)
- Glibenclamide impairs stretch activated release of ANP in experimental acute heart failure (1998) (0)
- Anp Production Is Impaired in Acute Decompensated Heart Failure (2020) (0)
- Defective Collagen Turnover Due to Increased Tissue Inhibitor of Matrix Metalloproteinase-1 and 2 Expression with Aging is Associated with Cardiorenal Fibrosis and Dysfunction (2012) (0)
- C-Type natriuretic peptide: a potential urinary biomarker for renal remodeling and fibrosis during aging (2011) (0)
- Brief Rapid Communication Increased Endothelin in Experimental Heart Failure (2005) (0)
- The Development of Heart Failure in Diabetic Patients with Preclinical Diastolic Dysfunction: A Population Based Study (2008) (0)
- Abstract 382: Kidney-Heart Connection: One Kidney Nephrectomy Results in Cardiac Fibrosis and Differential Ventricular Gene Profiles in the Absence of Heart Failure (2007) (0)
- Abstract 21316: Improved Renal Function With Continuous Flow Left Ventricular Assist Support is Associated With Aortic Valve Opening at 3 Months (2010) (0)
- Activation of heme-free soluble guanylate cyclase with cinaciguat has beneficial cardiorenal actions when added to furosemide in experimental heart failure (2011) (0)
- Murine Transverse Aortic Constriction (TAC) Is a Highly Variable Experimental Model Which Mimics Hypertensive Remodeling in Human Hypertension (2009) (0)
- 222 Oral conjugated human BNP activates cGMP and lowers blood pressure in normal conscious dogs (2005) (0)
- OE-326 A Multi-Targeting Chronic Neurohumoral Therapy with Sampatrilat in Experimental Congestive Heart Failure : Neurohumoral, Renal and Clinical Actions(OE55,Heart Failure (Treatment) 2 (M),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society) (2009) (0)
- Heart-Kidney Connection: Myocardial Infarction Induces Renal Cortical and Medullary Fibrosis and Activation of Renal Molecular Remodeling in the Absence of Heart Failure (2008) (0)
- PCV15 COMPARATIVE EFFECTIVENESS OF SACUBITRIL-VALSARTAN VERSUS ANGIOTENSIN CONVERTING ENZYME INHIBITORS / ANGIOTENSIN RECEPTOR BLOCKERS THERAPY ON RENAL OUTCOMES IN SYSTOLIC HEART FAILURE PATIENTS (2020) (0)
- 172. B-Type Natriuretic Peptide Gene Therapy as a Novel Early Treatment for Familial Hypertrophic Cardiomyopathy (2016) (0)
- Elevated plasma fibroblast growth factor 23 in patients with acute decompensated heart failure is independent of renal function and is of non-cardiac origin (2013) (0)
- The Prohormone of B-Type Natriuretic Peptide, proBNP1-108, Is Secreted by the Failing and Non-Failing Human Heart (2011) (0)
- Pro-Atrial Natriuretic Peptide In Vitro and In Vivo Normal Canines: A Selective Renal Enhancing Therapeutic (2013) (0)
- 930-106 Potentiation of Atrial Natriuretic Peptide Mediated Coronary Vasodilatation by Beta Adrenergic Stimulation (1995) (0)
- Natriuretic Peptide , in Experimental Severe Congestive Heart Failure Therapeutic Actions of a New Synthetic Vasoactive and Natriuretic Peptide , Dendroaspis (2001) (0)
- Cardiac Resynchronization Therapy Improves Renal Function in Heart Failure Patients with Reduced Glomerular Filtration Rate (2007) (0)
- Abstract 1946: Hyperaldosteronism Mediates Reduced Circulating Progenitor Cell Counts in Cardiac Failure (2007) (0)
- Atrial natriuretic fator (1987) (0)
- Increase in Left Ventricular Pro-Fibrotic Genes with LVAD Therapy and Potential Anti-Fibrotic Therapeutic Properties of the Novel Designer Natriuretic Peptide CD-NP in Cultured Human Cardiac Fibroblasts (2011) (0)
- Chronic Administration with Cenderitide Goes Beyond Enalapril in Cardiorenal Function and Anti-Remodeling Through Reverse Activation of Gene Pathways in Experimental Heart Failure (2016) (0)
- Guanylyl cyclase-B plays an important role in adipogenesis and “browning” of white fat (2013) (0)
- Correlation of Ejection Fraction to Early Post-Discharge Sudden Death and All-Cause Mortality in The EVEREST Trial (2008) (0)
- The QRS Interval Predicts Mortality and Re-Hospitalization in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
- 481 B-type natriuretic peptide enhances natriuretic actions of furosemide, suppresses furosemide-induced aldosterone activation and increases GFR in heart failure (2003) (0)
- Endothelium in early atherosclerosis (1994) (0)
- Regional Differences in Baseline Characteristics and Outcomes in Patients Hospitalized with Worsening Heart Failure and Systolic Dysfunction (2007) (0)
- Abstract 12581: Impaired Atrial Natriuretic Peptide Activation and Natriuresis in Response to Acute Volume Overload in Preclinical Diastolic and Systolic Dysfunction (2010) (0)
- Neurohormonal Profile of a Novel Chimeric Natriuretic Peptide, CD-NP, as Compared to C-Type Natriuretic Peptide, in the Normal Dog (2007) (0)
- Sex Differences In Hypertrophic Remodeling and Heart Failure in Mice Lacking Natriuretic Peptide Receptor A (2010) (0)
- 468 Additional particulate guanylate cyclase activation with BNP does not augment the hemodynamic actions of the direct soluble guanylate cyclase activator BAY 58‐2667 but it enhances renal function (2004) (0)
- Cardiorenal Actions of the Designer Natriuretic Peptide, CD-NP, in a Severe Heart Failure Model Treated with Furosemide (2011) (0)
- Chronic PDE V Inhibition in a Canine Model of Severe Experimental Heart Failure Altered Many Gene Expression in the Kidney Including Decreased Dipeptidyl Peptidase IV Gene Expression (2008) (0)
- Novel Protein Therapeutics for Human Preclinical Diastolic Dysfunction (Stage B Heart Failure): Chronic SQ BNP Administration (2013) (0)
- Cardiac failure: Editorial overview (1990) (0)
- Cardiac, Atrial Peptide, and Renal Responses to Acute Graded Volume Expansion (1986) (0)
- Response to Do Commercially Available Assay Kits for B-Type Natriuretic Peptide Measure Pro-BNP1-108, as Well as BNP1-32? (2007) (0)
- Utility of neurohumoral profiles in pulmonary hypertension: clinical and hemodynamic correlations (2003) (0)
- Cardiorenal Connection: Uninephrectomy Results in Cardiac Gene Changes Despite Normal Cardiac Function (2007) (0)
- BNP preserves endothelial cell integrity: modulation by atherosclerosis and vasopeptidase inhibition (2002) (0)
- O-9: Hemodynamic versus specialist hypertension management: Results of a randomized trial (2001) (0)
- B-type Natriuretic Peptide Molecular Forms and Their Convertases in Heart Failure (2011) (0)
- Cardiorenal Actions of Atrial Natriuretic Peptide in Angiotensin II Hypertension (1986) (0)
- The Novel Dual Natriuretic Peptide Receptor Activator CD-NP Decreases Fibrosis and Improves Diastolic Dysfunction Produced by Mild Renal Insufficiency (2010) (0)
- Abstract 10: Hyeprtension (2021) (0)
- P-376: Cardiorenal activation of adrenomedullin in experimental atherosclerosis (2001) (0)
- The prevalence of clinical and preclinical diastolic dysfunction in the community (2003) (0)
- Oral administration of newly developed conjugated form of human brain natriuretic peptide reduced blood pressure and enhances CGMP production in normal conscious dogs (2004) (0)
- Integrin receptor subtype antagonism augments BNP-mediated cGMP generation in cultured human cardiac fibroblasts: evidence for particulate guanylate cyclase receptor and integrin receptor cross-talk (2007) (0)
- B-type natriuretic peptide single nucleotide polymorphism rs198389 and survival in the general community (2009) (0)
- Endothelin in Congestive Heart Failure: Pathophysiology and Therapeutic Implications (1997) (0)
- 1030-12 The Action of a Specific Natriuretic Peptide Receptor Antagonist (HS142-1) Upon Basal Coronary and Renal Vascular Resistances (1995) (0)
- Human natriuretic peptide clearance receptor is induced by insulin and is associated with metabolic parameters (2015) (0)
- Abstract 12583: The Predictive Utility of Circulating C-Type Natriuretic Peptide for Myocardial Infarction and Heart Failure in the General Population (2013) (0)
- Cardiac fibroblast actions of cardiotrophin-1 and its receptor complex with crosstalk with the endothelin system in vitro: modulation by early dilated cardiomyopathy (2002) (0)
- Abstract 12647: Widespread Activation of Kidney Injury and Remodeling Molecular Pathways in Experimental Heart Failure in Canines (2014) (0)
- Transition from Asymptomatic to Overt Systolic Heart Failure – Renal, Hemodynamic and Neurohumoral Adaptations (2008) (0)
- High Dose Rosuvastatin Does Not Alter Cardiorenal Function, Myocardial Structure or Neurohumoral Activation in a Model of Progressive Experimental Heart Failure (2008) (0)
- The role of the natriuretic peptides in the hemodynamic actions of vasopeptidase inhibition in asymptomatic left ventricular dysfunction (1999) (0)
- 403 Mineralocorticoid escape by the kidney in experimental asymptomatic left ventricular dysfunction: a compensatory element of early heart failure (2003) (0)
- Effects of phosphodiesterase V inhibition alone and in combination with BNP on cardiovascular and renal response to volume load in human preclinical diastolic dysfunction (2021) (0)
- The role of atrial natriuretic factor and related peptides in congestive heart failure (1992) (0)
- Prognostic Implications of Urinary and Plasma C-type Natriuretic Peptide in Human Acute Decompensated Heart Failure (2020) (0)
- Acute Subcutaneous and Oral Delivery of Cenderitide, a Novel Dual Natriuretic Peptide Receptor Agonist, is Readily Absorbed and Activates the Second Messenger CGMP (2012) (0)
- The magnitude of decrease in hepatic VLDL ApoB secretion, in vivo, is determined by the extent of HMG-CoA reductase inhibition (1999) (0)
- Soluble Guanylate Cyclase (2009) (0)
- SERUM INSULIN DEGRADING ENZYME IS DETECTABLE IN HUMAN HEART FAILURE AND POSITIVELY CORRELATED WITH INCREASING CIRCULATING B-TYPE NATRIURETIC PEPTIDE (2023) (0)
- Increase in Myocardial Pro-Fibrotic Genes with LVAD and Potential Anti-fibrotic Properties of a Novel Peptide CD-NP in Human Cardiac Fibroblasts (2011) (0)
- Abstract 12954: Impairment of the Compensatory Natriuretic Peptide Response to Myocardial Infarction in the Aged is Associated With Adverse Cardiorenal Repair and Heart Failure (2014) (0)
- CD‐NP: A novel aldosterone‐suppressing designer natriuretic peptide in a first‐in‐human study (2009) (0)
- Abstract 17801: Subcutaneous Delivery of M-ANP, a Designer Natriuretic Peptide and Guanylyl Cyclase-A Stimulator, Potently Activates Cyclic GMP and Reduces Blood Pressure in Conscious Canines (2012) (0)
- Natriuretic peptide receptors in cardiac fibroblasts: a novel strategy to potentiate NPR-A receptor activation by ANP (2004) (0)
- BNP enhances renal actions of furosemide and suppresses furosemide-induced aldosterone activation in canine experimental heart failure (2003) (0)
- Abstract 12949: Increase in Left Ventricular Fibrosis With LVAD Therapy and in Model of Mechanical Unloading and Potential Anti-Fibrotic Therapy of the Novel Designer Natriuretic Peptide CD-NP in vitro (2011) (0)
- Aldosterone in the General Community: Biomarker or Mediator of Cardiorenal and Metabolic Disease (2013) (0)
- Human Preclinical Systolic and Diastolic Dysfunction Is Characterized by Impaired Cardiorenal Endocrine Response to Acute Volume Overload (2010) (0)
- PE-067 Effect of Chronic PDE-5 Inhibition on Myocardial Structure and Function in Mice with Pressure Overload : Interaction with Natriuretic Peptide Signaling(PE012,Heart Failure (Treatment) 1 (M),Poster Session (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society) (2009) (0)
- Subcutaneous Deliver of M-ANP in Conscious Canines: An Innovative Designer Guanylyl Cyclase A Receptor Activator for Cardiovascular Disease (2012) (0)
- NT-pro-BNP in male volunteers and urinary excretion of relaxin, NT-pro-ANP, and Effects of tilting and volume loading on plasma levels (2015) (0)
- PROGRESSIVE STRAIN IMAGING CHANGE AND ROLE OF THE NATRIURETIC PEPTIDES AS PREDICTORS OF LEFT VENTRICULAR DYSFUNCTION AND FIBROSIS IN AGING MYOCARDIUM (2010) (0)
- Abstract 11603: Structural Insights Into C-terminus and N-terminus of a Designer cGMP Activating ANP-Based Antihypertensive Peptide: ZD100 (2016) (0)
- Impaired Cardiorenal Adaptation to Acute Heart Failure and Volume Expansion in a Large Animal Model of Mild Renal Insufficiency: New Insights Into the Kidney-Heart Connection (2012) (0)
- [Management of heart failure in infants and children and infants in the 90s]. (1996) (0)
- A novel aquaretic and GFR enhancing peptide without vascular vasodilatory actions in experimental CHF (2007) (0)
- Metalloproteinases Brain Natriuretic Peptide Is Produced in Cardiac Fibroblasts and Induces Matrix (2002) (0)
- Acute and chronic effect of subcutaneous brain natriuretic peptide in experimental diastolic heart failure (2004) (0)
- Abstract 15766: Protein Disulfide Isomerase (PDI) Activity Enhances cGMP Generation by Natriuretic Peptides (2011) (0)
- 579 Phosphodiesterase V inhibition has favorable effects on LV remodeling and potentiates the renal actions of subcutaneously administered BNP in experimental overt congestive heart failure (2005) (0)
- Natriuretic Peptides and Cardiac Function (2020) (0)
- Matrix Metalloproteinases and Their Endogenous Inhibitors: Association with Ventricular Remodeling, Diastolic Dysfunction and Heart Failure in the Community (2006) (0)
- Abstract 11349: The Natriuretic Peptide Prohormones are Processed into Active Peptides in the Normal Human Circulation and the Processing is Preserved in Heart Failure (2012) (0)
- The renal response to acute neutral endopeptidase inhibition is determined by the severity of heart failure (1998) (0)
- Mild Renal Insufficiency Results in Increases in Myocardial Collagen: Evidence for a Heart – Kidney Connection (2008) (0)
- Clinical Trial: Methods & Design Rationale and Design of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy of B-Type Natriuretic Peptide for the Preservation of Left Ventricular Function After Anterior Myocardial Infarction (2013) (0)
- 1049-110 Circulating beta-atrial natriuretic peptide in human coronary artery disease: A new marker for stage A heart failure? (2004) (0)
- Receptor guanylyl cyclase (RGC) family in GtoPdb v.2021.3 (2021) (0)
- 092 - MANP: Structural Insights of a Novel GC-A Receptor and cGMP Activator with Cardiorenal Enhancing and Aldosterone Suppressing Actions in Vivo (2017) (0)
- Plasma Renin Activity (PRA) on Admission Predicts Diuretic Resistance and Mortality in Decompensated Heart Failure (HF) Patients with Renal Dysfunction (RD) (2010) (0)
- hemodynamics and ventricular function in the dog Actions of a novel synthetic natriuretic peptide on (2016) (0)
- Circulating Molecular Forms of C-Type Natriuretic Peptide in Aging Humans and Their Biological Actions in Cultured Human Cardiac Fibroblasts: A Potential Therapeutic and Diagnostic Opportunity (2012) (0)
- Activation of pulmonary neutral endopeptidase in experimental congestive heart failure (1997) (0)
- Cardiac Micro-CT Demonstrates Alterations in the Aging Coronary Vasculature in Association With Myocardial Fibrosis (2012) (0)
- Acknowledgment to Reviewers (1998) (0)
- Kidney-Heart Connection: Experimental Mild Renal Insufficiency Induces Early Cardiac Fibrosis and Myocardial Diastolic Dysfunction Followed by Late Systolic Failure (2008) (0)
- Release of adrenomedullin from the failing human ventricle (1996) (0)
- Atrial Natriuretic Peptide Mediates Reverse Cardiac Remodeling During Treatment with Sacubitril/Valsartan in Patients with Heart Failure with Reduced Ejection Fraction (2020) (0)
- Subcutaneous BNP administration in experimental mild heart failure: A novel therapeutic strategy (1998) (0)
- ANP SPECIFIC DEFICIENCY AND CARDIOMETABOLIC DISEASE IN MALES IN THE GENERAL COMMUNITY (2022) (0)
- Determinants of Circulating Corin in Healthy Subjects (2009) (0)
- A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction (2013) (0)
- PRESENCE OF A NATRIURETIC PEPTIDE DEFICIENCY STATE AMONGST PATIENTS DIAGNOSED WITH HYPERTENSION (2019) (0)
- Cardiotrophin-1 Stimulates Endothelin-1 Synthesis and Secretion From Vascular Endothelial Cells (2002) (0)
- Coadministration of B-type natriuretic peptide and the vasopressin-2 receptor antagonist tolvaptan: a novel physiologic strategy to enhance water and sodium excretion without adversely affecting renal or neurohumoral function in experimental congestive heart failure (2007) (0)
- Designer Natriuretic Peptides for Heart Failure (2011) (0)
- Endothelial Function in Humans Long-term L-Arginine Supplementation Improves Small-Vessel Coronary (1998) (0)
- Plasma Aldosterone and Heart Failure in the General Community (2015) (0)
- Bioavailability of intravenous versus subcutaneous administration of the dual GC-A and GC-B designer natriuretic peptide cenderitide in healthy canines (2011) (0)
- P-375: Atheroma-inhibiting and vasoprotective properties of CO-targeting neutral endopeptidase and angiotensin converting enzyme (2001) (0)
- DIFFERENTIAL REGULATION OF CIRCULATING CARDIAC NATRIURETIC PEPTIDES IN HUMAN ACUTE DECOMPENSATED HEART FAILURE: EVIDENCE FOR A SELECTIVE AND RELATIVE ATRIAL NATRIURETIC PEPTIDE DEFICIENCY (2018) (0)
- A genetic variant of soluble guanylate cyclase is associated with higher plasma cholesterol and triglycerides in the general population (2014) (0)
- Differential actions of cardiac resynchronization therapy upon ANP and BNP in patients with non-ischemic and ischemic cardiomyopathy (2004) (0)
- CRRL269 AS AN INNOVATIVE PARTICULATE GUANYLYL CYCLASE RECEPTOR (GC-A) PEPTIDE ACTIVATOR FOR ACUTE KIDNEY INJURY TREATMENT (2019) (0)
- Cyclic GMP stimulating actions of a novel fully humanized designer natriuretic peptide, CBB‐NP, in human aortic endothelial cells as compared to the native natriuretic peptides (2009) (0)
- Myocardial Pronatriuretic Peptide Convertase Furin in the Presence and Absence of Experimental Heart Failure (2010) (0)
- Brain natriuretic peptide is a cost-effective diagnostic marker of ventricular dysfunction (1998) (0)
- Furosemide-Induced Aldosterone Activation in Experimental Heart Failure Brain Natriuretic Peptide Enhances Renal Actions of Furosemide and Suppresses (2004) (0)
- Subcutaneous administration of biologically active novel conjugates of human BNP in normal conscious dogs (2004) (0)
- Defining Mechanisms of Myocardial Fibrosis in Experimental Mild Renal Insufficiency: A Role for TGF-β1 Receptor and Molecular Ubiquitin Ligase NFKB Gene Activation in a Kidney-Heart Connection (2009) (0)
- Abstract 1683: Chronic Renal Insufficiency: Prevalence in the General Population and Improved Detection of Cardiac Disease in Combination With BNP Assays (2009) (0)
- Abstract 12238: Myocardial Injury Induces Renal Fibrosis and Dysfunction in Association With the Activation of Renal Apoptotic and TGF-Beta Molecular Pathways (2015) (0)
- A novel designer natriuretic peptide CD-NP suppresses TGF-beta 1 induced collagen Type I production in human cardiac fibroblasts (2009) (0)
- Antifibrotic property of brain natriuretic peptide in cardiac fibroblasts: Cross-talk action with endothelin-1 and tumor necrosis factor on the induction of matrix metalloproteinases (2003) (0)
- Cardiotrophin-1 gene expression in experimental congestive heart failure is activated and correlates with ventricular hypertrophy (1999) (0)
- Angiotensin II As A Natural Suppressor On Cardiac Natriuretic Peptide System: Molecular Insights And Novel Therapeutic Design (2022) (0)
- Abstract 3478: Evidence for Differential Modulation of the Cardiorenal Actions of B-Type Natriuretic Peptide by the Peptidases Dipeptidyl Peptidase IV and Meprin A (2008) (0)
- Can B-Type Natriuretic Peptide Predict Patients Who Will Have Significant Reverse Remodelling with Cardiac Resynchronization Therapy? (2006) (0)
- Cardiorenal actions of a unique chimeric peptide to CNP and BNP in experimental chronic heart failure (2003) (0)
- Mechanism of the dissimilar sodium re absorptive response to renal vein constriction in hydropenia and volume expansion (1980) (0)
- EVIDENCE FOR ANGIOTENSIN II AS A NATURALLY EXISTING SUPPRESSOR FOR THE NATRIURETIC PEPTIDE SYSTEM (2023) (0)
- Heart – Kidney Connection: Myocardial Infarction Induces Widespread Changes in Renal Cortical and Medullary Gene Expression together with Cortical and Medullary Fibrosis (2008) (0)
- The Kidney–Heart Connection: Experimental Mild Renal Insufficiency Mediates Molecular Ventricular Remodeling and Fibrosis (2007) (0)
- Abstract 1599: Beneficial Renal and Anti-Aldosterone Actions of Combined B-Type Natriuretic Peptide and Vasopressin-2 Receptor Antagonism with Tolvaptan in Experimental Congestive Heart Failure (2007) (0)
- Modulating cGMP in heart failure by novel natriuretic peptides (2009) (0)
- OE-323 A Human Atrial Natriuretic Peptide Gene Mutation Reveals a Novel C-terminally Extended Peptide with Enhanced Renal and Renin-Aldosterone Auppressing Actions(OE55,Heart Failure (Treatment) 2 (M),Oral Presentation (English),The 73rd Annual Scientific Meeting of The Japanese Circulation Society) (2009) (0)
- Renal Failure After Angiography (1985) (0)
- Effect of cardiac resynchronization therapy on serum creatinine levels in patients with congestive heart failure (2004) (0)
- Early Experimental Chronic Kidney Disease Activates Myocardial Apoptotic Genes and Leads to Early Myocardial Fibrosis (2011) (0)
- Atrial natriuretic peptide and blood pressure. (1996) (0)
- Abstract 386: A Novel Aquaretic and Glomerular Filtration Rate Enhancing Peptide Without Vascular Vasodilatory Actions in Experimental CHF. (2007) (0)
- O-35: Blood pressure lowering, renin suppressing and natriuretic properties of a new designer peptide BD-NP (2001) (0)
- Plasma Brain Natriuretic Peptide for the Detection of Pre-Clinical Systolic Dysfunction in the General Population (2003) (0)
- Cardiorenal actions of the new heme-independent direct soluble guanylate cyclase stimulator BAY 58-2667 in experimental congestive heart failure (2003) (0)
- Abstract 14893: Structural Variant of the Designer Peptide MANP: Differential Actions With cGMP Activation in Cardiorenal Functions (2017) (0)
- The action of intrarenal endothelin in the dog (1991) (0)
- P mino-Terminal ProB-Type atriuretic Peptide and B-Type atriuretic Peptide in the General Community eterminants and Detection of Left Ventricular Dysfunction (2016) (0)
- LEFT ATRIAL DIAMETER AND VOLUME Left Atrial Size by Planimetry is Superior to M-mode Diameter: Biochemical Calibration by Atrial and Brain Natriuretic Peptide (2008) (0)
- MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results (2015) (0)
- Abstract 15838: Atrial Natriuretic Peptide Compensatory Response is Impaired in Human Acute Decompensated Heart Failure (2020) (0)
- Novel Alternatively Spliced Form of Natriuretic Peptide Convertase Corin (2010) (0)
- Comment Atrial Natriuretic Factor Is It Physiologically Important ? (2005) (0)
- A Genetic Variant of the ANP Gene Is Associated With a Lower Cardiometabolic Risk Profile in the General USA Population (2010) (0)
- Abstract 11026: Aldosterone Level in the General Community Predicts New Onset Cardiometabolic Disease (2014) (0)
- Treatment with CBA-NP a novel chimeric natriuretic peptide attenuates cardiorenal fibrosis and improves diastolic dysfunction in diabetic rat model (2011) (0)
- Furin and Corin Process Human ProBNP to Unique BNP Forms In Vitro with Differential Regulation of Furin and Corin in Models of Experimental Heart Failure (2008) (0)
- The natriuretic peptide receptors are present in human and canine cardiac fibrobalsts (2003) (0)
- Genetic deletion in the mouse of the ANP gene augments while subcutaneous BNP prevents ventricular remodeling after myocardial infarction (2003) (0)
- Renal Remodeling Post Myocardial Infarction: The Modulating Actions of Aging (2011) (0)
- Attenuated ANF-mediated nephrogenous cyclic GMP gensation in advanced congestive heart failure (1991) (0)
- The ANP Genetic Variant RS5068 is Associated With a Favorable Cardiometabolic Phenotype in a Mediterranean Population (2012) (0)
- 1012-105 Endothelin Immunoreactivity in Human Coronary Atherosclerosis (1995) (0)
- BUNP: A Novel Designer pGC-A/cGMP Activator with Enhanced Potency and High Selectivity In Vitro (2016) (0)
- Pro-B-Type Natriuretic Peptide Predicts Mortality and Cardiovascular Events in the General Community: Comparison to Other BNP Biomarkers (2010) (0)
- Novel Renal Targeted Protein Therapeutics in Experimental Overt Heart Failure and Renal Dysfunction with an Innovative Chimeric Natriuretic Peptide: ABC-NP (2008) (0)
- Natriuretic peptides in patients with mitral regurgitation: markers of degree or consequences of the regurgitation? (1998) (0)
- Inhibition of endothelial-derived relaxing factor enhances the coronary vasoconstriction to endothelin-B activation (1996) (0)
- Subcutaneous MANP, a novel particulate GC-A peptide agonist which is resistant to neprilysin degradation, possesses greater blood pressuring lowering actions in vivo compared to ANP (2016) (0)
- Repeated Chronic Measurements Demonstrate Less Variability in NT-proANP Compared to ANP or BNP in Stable CHF, and Compared to ANP in Subjects Recently Hospitalized with CHF (2008) (0)
- Irish Cardiac Society Proceedings of meeting held 23rd–24th November, 1990 (1991) (0)
- The FDA and the New Biology (2008) (0)
- A010: Selective effects of angiotensin II (AII) and endothelin (ET) in regional hemodynamics and renal function in anesthetized dogs (1998) (0)
- Abstract 15258: Radiation Induced Coronary Microvascular Compromise; a Novel Rodent Model of Heart Failure With Preserved Ejection Fraction (2016) (0)
- MANP Activation Of The cGMP Inhibits Aldosterone Via PDE2 And CYP11B2 In H295R Cells And In Mice (2022) (0)
- P-657: Acute oral pegylated human BNP activates cGMP and decreases mean arterial pressure in normal dogs (2005) (0)
- Expression and Co-Localization of C-Type Natriuretic Peptide and Endothelin in Human Kidney (2000) (0)
- Chronic subcutaneous administration of the cardiac peptide BNP in experimental heart failure does not result in the development of tolerance to exogenous BNP (2003) (0)
- Defining the acute cardiorenal response to high dose nesiritide in experimental severe congestive heart failure (2003) (0)
- SACUBITRIL/VALSARTAN PROTEOMIC BIOMARKERS FOR HEART FAILURE WITH PRESERVED EJECTION FRACTION: MOLECULAR INSIGHTS ASSOCIATED WITH SEX DIFFERENCES IN DRUG RESPONSE (2022) (0)
- Remodeling and aratio (2016) (0)
- 4934Circulating molecular forms of ANP and BNP in human acute decompensated Heart Failure: evidence for a relative ANP deficiency state (2018) (0)
- Post-Discharge Adjudicated Outcomes in Patients with Implantable Cardioverter-Defibrillators in the EVEREST Trial (2008) (0)
- Chronic Phosphodiesterase-5 Inhibition Ameliorates Myocardial Contractile Dysfunction in Elderly Canine Model of Hypertensive Heart Disease (2008) (0)
- Atrial natriuretic factor prevents radiocontrast-induced nephropathy in dogs with experimental heart failure (1990) (0)
- Effect of adrenomedullin on load and myocardial function before and after experimental heart failure (1999) (0)
- Atrial natriuretic factor [3] (1991) (0)
- Abstract 20240: CD-NP, a Novel Dual Guanylyl Cyclase Receptor Activator, Decreases Fibrosis and Improves Diastolic Dysfunction Produced by Mild Renal Insufficiency (2010) (0)
- Chronic Subcutaneous BNP Administration in Human Preclinical Systolic Dysfunction (Stage B Heart Failure) Results in Sustained Renal Responsiveness to Acute Volume Overload (2013) (0)
- Abstract 11323: In vitro and in vivo Actions of Ang1-7/BNP: A Novel Chimeric Peptide With Dual Actions Through the Natriuretic Peptide and Mas Receptors (2013) (0)
- Natriutetic peptides inhibit endothelin-1 and angiotensin-II mediated human coronary smooth muscle cell proliferation (1996) (0)
- Augmenting renal function in experimental congestive heart failure by brain natriuretic peptide and lasix (2003) (0)
- Abstract 16098: Circulating Cyclic GMP: Relationship With Cardiovascular and Renal Disease in the General Community (2016) (0)
- MANP: a novel particulate guanylyl cyclase A receptor/cGMP activator for resistant hypertension: preliminary first in human clinical trial results (2015) (0)
- Relationship in humans between atrial natriuretic peptide and arginine vasopressin during dehydration (1986) (0)
- Pharmacokinetics of subcutaneous delivery of M-ANP: an innovative designer anp-based guanylyl cyclase activating peptide for hypertension (2014) (0)
- Mutation of three amino acids in the disulfide-ring of a CNP based chimeric natriuretic peptide alters its vascular properties (2008) (0)
- A novel particulate guanylyl cyclase receptor B/cGMP activator with selective vasodilating actions in experimental hypertension (2016) (0)
- Hemodynamic actions of endothelin in a low atrial natriuretic factor model of heart failure (1991) (0)
- The natriuretic peptide system: Continuing advances in biology and therapeutics (1995) (0)
- 65 Design, synthesis and unique biological actions of CD‐NP: a novel CNP‐like chimeric natriuretic peptide (2007) (0)
- Molecular Phenotyping of the Natriuretic Peptide and Renin-Angiotensin Systems in the Post-Myocardial Infarction Left Ventricle and Scar (2016) (0)
- Abstract 10303: CRRL290: A Novel and Mechanism-Based Therapeutic Peptide Targeting the Crosstalk Between Angiotensin II and the Natriuretic Peptide System for Cardiorenal Disease (2021) (0)
- 35 Regional differences in baseline characteristics and outcomes in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
- MANP: A novel designer natriuretic peptide GC-A activator for the treatment of hypertension and heart failure (2014) (0)
- Abstract 1497: A Novel Designer Natriuretic Peptide, CAA-NP, as Assessed in Human Aortic Endothelial Cells: Evidence for Involvement of Natriuretic Peptide Receptor-A (NPR-A) and NPR-B in Cyclic GMP Response (2008) (0)
- CRRL191: A NOVEL BIOENGINEERED PEPTIDE ACTIVATOR OF THE GUANYLYL CYCLASE A RECEPTOR THAT HAS MORE POTENT AND LONG-LASTING BLOOD PRESSURE LOWERING AND RENAL ENHANCING ACTIONS THAN ATRIAL NATRIURETIC PEPTIDE (2023) (0)
- Natriuretic and anti-aldosterone actions of chronic oral neutral endopeptidase inhibition during the progression of experimental congestive heart failure (2004) (0)
- Novel Natriuretic Peptides and the Cardiorenal Syndrome (2015) (0)
- A Novel Orally Active BNP Possesses Chronic Natriureti Actions, Decreases Mean Arterial Pressure and Activates cGMP in a Model of Acute Hypertension (2008) (0)
- Abstract 12347: C53: An Innovative GC-B Activating Drug Targeting Cardiorenal Fibrosis and the Progression to CKD-induced Heart Failure (2019) (0)
- The degree of natriuretic peptide system activation in stable and high risk CHF characterized by increased cystatin C is not reflected in cGMP activation (2009) (0)
- 1014-97 Increase in Ventricular Adrenomedullin in the Failing Human Heart (1995) (0)
- 028 - C53: A Novel CNP-Based Therapeutic Strategy Targeting Cardiac Fibrosis and Heart Failure (2017) (0)
- A biodegradable in-situ polymer precipitation delivery system for sustained delivery of a novel chimeric natriuretic peptide CD-NP in an experimental model of myocardial infarction (2013) (0)
- Experimental Studies Attenuated Natriuretic Response to Adrenomedullin in Experimental Heart Failure (2001) (0)
- Effects of Tolvaptan in Patients Hospitalized with Heart Failure and Renal Impairment and Hypotension in the EVEREST Trial (2008) (0)
- to the development of symptoms Progression of preclinical diastolic dysfunction (0)
- The Heart-Kidney Connection: Myocardial Infarction Accelerates Glomerular Dysfunction, Hypertrophy and Proteinuria in the Presence of Experimental Mild Renal Insufficiency (2006) (0)
- Abstract 12636: Pro-Atrial Natriuretic Peptide: A Novel Guanylyl Cyclase-A Receptor Activator Which Goes Beyond Carperitide and Nesiritide (2014) (0)
- Cardiac Specific Gene Delivery of a Dual GC-A and GC-B Agonist, CD-NP, Mediates Anti-Hypertrophic Actions in a Model of Hypertensive Heart Disease beyond GC-A Activation Alone Via BNP (2012) (0)
- EVIDENCE FOR CYCLIC GUANOSINE MONOPHOSPHATE IMPAIRMENT IN ACUTE DECOMPENSATED HEART FAILURE PATIENTS (2019) (0)
- Progressive Bi-Ventricular Dysfunction in a Large Animal Model of Heart Failure With Rapid Ventricular Pacing: Echocardiographic Parameters and Invasive Characterization (2012) (0)
- VALIDATION OF AN ANP DEFICIENCY IN ACUTE DECOMPENSATED HEART FAILURE THROUGH ANALYSES OF BIOLOGICALLY IN-ACTIVE NATRIURETIC PEPTIDES (2020) (0)
- e0624 The effect of cardiac resynchronisation therapy on novel neurohormones in heart failure (2010) (0)
- 395 Ryanodine receptor activation in the kidney in vivo by the cardioprotective agent K201 is natriuretic and GFR enhancing (2005) (0)
- Enhancing cGMP With Sildenafil and BNP Acutely Reduces Diastolic Stiffness in Experimental Diastolic Heart Failure (2010) (0)
- The Soluble Guanylate Cyclase Genetic Variant rs13139571 Is Associated with an “Unfavorable” Metabolic Phenotype in an US General Community (2014) (0)
- Effect of cardiac resynchronization therapy on plasma catecholamines in patients with and without beta-blocker therapy (2004) (0)
- Abstract 5265: Alternatively Spliced B-Type Natriuretic Peptide (ASBNP) is a Renal Selective Natriuretic and Diuretic Peptide Without Hypotensive Properties (2009) (0)
- 095 - A Phase I, Placebo Controlled Cross-Over Study of Subcutaneous Cenderitide with LVAD Support a Phase I, Placebo Controlled Cross-Over Study of Subcutaneous Cenderitide with LVAD Support (2017) (0)
- Chronic Cardiac Gene Delivery of proBNP in Experimental Progressive Hypertensive Heart Disease Improves Survival (2011) (0)
- 267 Effects of tolvaptan on physician-assessed signs and symptoms in patients admitted with acute heart failure - results from the EVEREST program (2008) (0)
- Ventricular gene expression of adrenomedullin is increased in experimental heart failure (1998) (0)
- Gene Expression Profiling in Experimental Early Stage Heart Failure Reveals Activation of Molecular Pathways of Fibrosis and Inflammation in the Kidney and Heart (2014) (0)
- New Orally Available Human BNP Lowers Blood Pressure and Activates cGMP in Normal Conscious Dogs: 4.7 (2005) (0)
- Acute Blood Pressure, Renal and cGMP Responses to the Novel Designer Natriuretic Peptide ZD100 in Spontaneously Hypertensive Rats (2015) (0)
- Burden of cardiorenal disease in the United States general adult population (2002) (0)
- INTRARENAL RENIN ANGIOTENSIN SYSTEM ACTIVATION: PATHOPHYSIOLOGIC AND THERAPEUTIC IMPLICATIONS IN ACUTE DECOMPENSATED HEART FAILURE (2017) (0)
- 40 The BNP genetic variant rs198389: hypertension risk and cardiovascular phenotype in stage A and stage B heart failure subjects from the STOP-HF trial (2018) (0)
- 779-4 Biphasic Alterations in Plasma Nitric Oxide in Experimental Progressive Heart Failure (1995) (0)
- Erratum: Biomarker responses during and after treatment with nesiritide infusion in patients with decompensated chronic heart failure (Clinical Chemistry (2001) 51 (569-577)) (2005) (0)
- Relative Utility of Health ABC Risk Score, NT-proBNP and Systolic Function as Heart Failure Screening Tools in the General Community (2013) (0)
- Renal targeted protein therapeutics in experimental overt heart failure with renal dysfunction (2008) (0)
- Biomarkers, mineralocorticoid receptor antagonism, and cardiorenal remodeling. (2015) (0)
- Ethnicity Impacts proBNP1-108 and BNP Levels in Hypertensive Caucasians and Hispanics (2010) (0)
- Abstract P140: A Novel New Generation Designer Natriuretic Peptide, CBB-NP, Exerts Favorable Cardiorenal and Neurohumoral Actions (2008) (0)
- Novel Large Animal Model of Acute Experimental Hypertensive Heart Failure (2010) (0)
- The Kidney, Bone Marrow, and Heart Connection in Acute Kidney Injury (2019) (0)
- VASOPEPTIDASE-INHIBITOR OMAPATRILAT (1999) (0)
- Soluble and Particulate Guanylate Cyclase Differentially Affect Cyclic Guanosine Monophosphate in Plasma and Urine (2008) (0)
- Cardiorenal actions of a novel chimeric natriuretic peptide, CD-NP, as compared to C-type natriuretic peptide, in the normal dog (2007) (0)
- Prevalence of Chronic Renal Insufficiency and Ventricular Remodeling in the General Population (2007) (0)
- 792 Cardiorenal actions of the new direct soluble guanylate cyclase activator BAY 58‐2667 in experimental congestive heart failure (2003) (0)
- Editorial Board (2011) (0)
- 581 The cardiac peptide BNP is superior to the renally derived peptide urodilatin and ANP in enhancing renal function in over experimental CHF (2003) (0)
- Abstract 11352: Dietary Sodium Restriction Results in Early Neurohormonal Activation in Experimental Progressive Heart Failure (2012) (0)
- Amino Terminal Pro-B-Type Natriuretic Peptide Predicts Mortality, Congestive Heart Failure, Stroke and Myocardial Infarction in the General Population but Not in the Absence of Traditional Cardiovascular Risk Factors or Structural Changes of the Heart (2009) (0)
- 757-4 Differential Regulation of Renal Cyclic Nucleotide Phosphodiesterases in Experimental Heart Failure (1995) (0)
- Abstract 6278: Burden of Chronic Renal Insufficiency in the General Population and Added Predictive Power of GFR to BNP and NT-proBNP in Detection of Altered Ventricular Structure and Function (2008) (0)
- Abstract 14450: Challenging Hypertension: M-Atrial Natriuretic Peptide Enhances Antihypertensive Actions of Furosemide and Attenuates the Activation of Aldosterone (2018) (0)
- 038 - Differential Regulation of Circulating and Urinary Renin-Angiotensin System in Acute Decompensated Heart Failure (2017) (0)
- 1116-11 The mineralocorticoid paradox: Profibrotic in vivo in experimental asymptomatic left ventricular dysfunction but antifibrotic in vitro (2004) (0)
- Guanylyl cyclase-B plays an important role in adipogenesis and “browning” of white fat (2013) (0)
- Abstract 19094: Antihypertensive Properties of Subcutaneous M-ANP, a Novel Designer Atrial Natriuretic Peptide, in a Canine Model of Chronic Angiotensin-II Induced Hypertension (2014) (0)
- 560 Differential activation of natriuretic peptides in human heart failure and relationship to cardiac function: evidence for peptide deficiency (2003) (0)
- Abstract 10140: Atrial Natriuretic Peptide Deficiency Associated with Greater Cardiometabolic Disease in Males (2021) (0)
- Forearm Resistance Vessels Induced Vasodilation Is Dependent On Hyperpolarization in − C-Type Natriuretic Peptide (2001) (0)
- Abstract 16186: Dyslipidemia May Represent a Cyclic GMP Deficiency State: Insights From a General Community (2016) (0)
- Selective activation of the endothelin-B receptor: Regional vascular actions in vivo (1996) (0)
- DESIGNER CHIMERIC NATRIURETIC PEPTIDE CBA-NP REDUCES MYOCARDIAL FIBROSIS AND IMPROVES CARDIO-HUMORAL ACTIONS IN EXPERIMENTAL DIABETIC CARDIOMYOPATHY (2011) (0)
- Acute subcutaneous BNP administration in human heart failure enhances diastolic function and filling pressures as assessed by doppler echocardiography and plasma ANP (2002) (0)
- Abstract 270: Decrease of BNP Concentrations in Blood Perfusing Extremities of Patients with Advanced Peripheral Arterial Disease (2012) (0)
- Abstract 17224: Genetic Association Study of Circulating NT-proANP in the General Community Identifies a Novel Gene Cluster Associated With Stroke (2013) (0)
- Chronic natriuretic peptide protein therapeutics (2013) (0)
- 727-5 Differential Role of Circulating and Ventricular ANP as a Marker for Cardiac Filling Pressures and Ventricular Remodeling in a Model of Pacing Induced Heart Failure and Cardiac Hypertrophy (1995) (0)
- Kidney in Acute Heart Failure (2008) (0)
- Sustained Acting Atrial Natriuretic Peptide: A Novel Renal Selective Natriuretic Peptide Synthesized from a Human Frameshift Mutation of the Atrial Natriuretic Peptide Gene (2009) (0)
- The Aging Heart Is at Risk for Excessive Structural Remodeling and Heart Failure Post Myocardial Infarction (2010) (0)
- EFFECT OF MANP, A NOVEL ANP ANALOG, ON THE CIRCULATING METABOLOME IN PATIENTS WITH HYPERTENSION AND METABOLIC SYNDROME (2023) (0)
- Abstract 3575: Patients With High Baseline Levels of B-Type Natriuretic Peptide are Less Likely to Experience Significant Left Ventricular Reverse Remodeling With Cardiac Resynchronization Therapy in the Multicenter InSync Randomized Clinical Evaluation (MIRACLE) Trial (2006) (0)
- B-type natriuretic peptide single nucleotide polymorphism rs198389 is highly prevalent and impacts test characteristics of common assays (2009) (0)
- M-atrial natriuretic peptide and nitroglycerin in experimental acute hypertensive heart failure: differential actions of two cGMP activating therapeutics (2013) (0)
- Aortic Valve Opening at Hospital Discharge After HeartMate II Left Ventricular Assist Device Implantation Is Associated With Improved Renal Function at 3 Months (2011) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With John C. Jr. Burnett?
John C. Jr. Burnett is affiliated with the following schools:
